Managing Young Women with Breast Cancer
Emirates Oncology Conference
25 – 27 November, 2022

Conrad Etihad Towers, Abu Dhabi

United Arab Emirates

  • About Us
    • Organizing Committee
    • Scientific Committee
    • Scientific Sub Committee
  • Welcome Message
  • Program
    • 2022 Program At Glance
    • Day 1 Program
    • Day 2 Program
    • Day 3 Program
    • Meet the Expert Session
    • Full Program
  • Speakers
  • 2022 Partners
  • Download CME
  • Media
    • EOC 2022 Gallery
      • Photo Gallery
      • Video Gallery
    • EOC 2021 Gallery
    • EOC 2016 Gallery
    • EOC 2015 Gallery
    • EOC 2014 Gallery
  • Contact Us
25 – 27 November, 2022

Conrad Etihad Towers, Abu Dhabi

United Arab Emirates

Quick Links  
Quick Links
  • 2022 Program At Glance
  • 2022 Speakers

2022 Program – Day 2

Home 2022 Program – Day 2

Day 1
Day 2
Day 3
HALL A
26 November 2022
HALL B
26 November 2022

Session 1: Early Breast Cancer Session
Chairperson:

Dr. Mouza Mohd Al Ameri | United Arab Emirates

Mouza
Dr. Mouza Mohd Al Ameri
Consultant Physician, Oncology – Breast Care Center (Dep) | United Arab Emirates

Mouza Al Ameri is a breast onco-plastic surgeon and assistant professor of surgery in UAE University and Tawam Hospital. She is passionate about breast cancer research, empowering breast cancer survivors and disseminate breast cancer awareness among society members.

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -


Chairperson:

Dr. Nouri Bennini | United Arab Emirates

Nouri
Dr. Nouri Bennini
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr.Nouri Bennini is a Consultant Physician, Oncology Clinic at Tawam Hospital.

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -


Chairperson:

Dr. Mohanad Diab | United Arab Emirates

Mohanad
Dr. Mohanad Diab
Consultant Medical Oncology | United Arab Emirates

Dr. Mohanad Diab is an established and highly skilled Consultant Medical Oncologist with over 12 years of experience in the field of Oncology. He pursued his MD in 2004 from Karolinska University, Sweden. He obtained his Certification in Bone Marrow Transplantation in 2008 from Oncology Hospital, Radiumhemmet. Dr. Diab spent the first half of his career in the hospitals of the West Gotland Region, Sweden, as a Consultant Medical Oncologist. In 2014, he relocated to UAE and served eight years as the Head of the Oncology Department in one of the leading private hospitals in Abu Dhabi before joining Burjeel Hospital, Abu Dhabi. He is well regarded for his active involvement in setting up a world-class oncology clinic and multi-disciplinary tumor board. His expertise is treating distinctive cancers through chemotherapy, targeted therapy, and immunotherapy. The conditions include brain cancer, oligodendroglioma, pancreatic cancer, colorectal cancer, meningioma, prostate cancer, mixed gliomas, lung cancer, ependymoma, metastatic cancer, oral cancer, primitive neuroectodermal tumor, breast cancer, cervical and ovarian cancer. He is an active contributor to the research & studies dedicated to the field of oncology and tumor diagnosis.

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -


Speaker:

Dr. Aydah Al Awadhi | United Arab Emirates

Aydah
Dr. Aydah Al Awadhi
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Aydah Al Awadhi is a Consultant Physician, Oncology Clinic at Tawam Hospital

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -


Speaker:

Dr. Emad Dawoud | United Arab Emirates

Emad
Dr. Emad Dawoud
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Emad Dawoud is a Consultant Medical Oncologist in Oncology department at Tawam hospital UAE, and Assistant professor of clinical oncology in Al Azhar University Cairo, Egypt. Dr. Dawoud has been principal investigator and co- investigator for more than 50 clinical trials and abstract published per reviewed journals and he is a member of various associations such as ASCO, ESMO, ESTRO.

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -


Speaker:

Dr. Sibylle Loibl | Germany

Sibylle
Dr. Sibylle Loibl
Chief Executive Officer | Germany

"Prof. Dr. Sibylle Loibl is Chair of the German Breast Group and the Chief Executive Officer of the GBG Forschungs GmbH. Prof. Dr. Loibl is an associate professor of obstetrics and gynaecology at the Goethe University of Frankfurt. She gained a doctorate at the Ruprecht Karl University of Heidelberg and trained as a consultant in gynaecology and obstetrics at the women’s clinics of the university hospitals in Heidelberg and Frankfurt am Main. She devotes most of her time to clinical research within the German Breast Group and clinical work at the Centre for Haematology and Oncology, Bethanien in Frankfurt. Prof. Dr. Loibl has gained international renommée for her research in neoadjuvant breast cancer, breast cancer during pregnancy and breast cancer in young women. She established the Translational Research Group within the German Breast Group and has headed numerous research projects. In addition, Prof. Dr. Loibl has been involved in conducting and managing a significant number of national and international, practice-changing clinical trials. Prof. Dr. Loibl is author of more than 400 original and peer-reviewed articles and scientific papers; she has written numerous books and book chapters. She is an active member of many important national and international organizations, such as ASCO, ESMO, DKG and the AGO. She is involved in national and international guidelines for breast cancer, amongst them those for ESMO and ASCO. She was the first Co-Chair of the ESMO Breast Conference in Berlin and is an active faculty member of many international (ASCO, ESMO, SABCS) conferences."

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -


Speaker:

Dr. Meteb Foheidi | Saudi Arabia

Meteb
Dr. Meteb Foheidi
Medical Oncology Consultant | Saudi Arabia

Dr. Meteb Foheidi is a medical oncology consultant at Princess Noorah Oncology Center, National Guard Health Affairs, Jeddah, Asistant Professor & Medical Oncology Block Cordinator at King Saud Bin Abdulaziz University for Health and Science – Jeddah and Western Oncology Group Director, Saudi Oncology Society.

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -


  08:30 - 11:00

Welcome Note

Dr. Mouza Mohd Al Ameri | United Arab Emirates

Mouza
Dr. Mouza Mohd Al Ameri
Consultant Physician, Oncology – Breast Care Center (Dep) | United Arab Emirates

Mouza Al Ameri is a breast onco-plastic surgeon and assistant professor of surgery in UAE University and Tawam Hospital. She is passionate about breast cancer research, empowering breast cancer survivors and disseminate breast cancer awareness among society members.

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

Saturday, 2022-11-26
Welcome Note

  08:30 - 08:31

  08:30 - 08:31

The Future of Breast Cancer Surgery

Dr. Stephen Grobmyer | United Arab Emirates

Stephen
Dr. Stephen Grobmyer
Institute Chair of the Oncology | United Arab Emirates

"Dr. Stephen R. Grobmyer, MD, is the Institute Chair of the Oncology Institute at Cleveland Clinic Abu Dhabi. Prior to joining Cleveland Clinic Abu Dhabi, Dr. Grobmyer was Professor of Surgery, Section Head of Breast Surgery and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program at Cleveland Clinic Main Campus in Cleveland, Ohio. Dr. Grobmyer received his medical degree from the University of Texas Southwestern Medical School in Dallas, Texas and completed his residency in General Surgery at New York Hospital-Cornell Medical Center in New York. He completed a fellowship in Surgical Oncology at Memorial Sloan Kettering in 2004. Dr. Grobmyer™s innovative clinical care and research focuses on developing new approaches to prevent, diagnose and treat breast cancer. He has published over 170 peer-reviewed manuscripts, twenty book chapters and edited a textbook on innovative cancer therapies. Additionally, he has given over one hundred invited lectures nationally and internationally. "

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

Saturday, 2022-11-26
The Future of Breast Cancer Surgery

  08:30 - 08:50

  08:30 - 08:50

Optimal management of early HER2 positive Breast cancer - Supported by Roche

Dr. Sibylle Loibl | Germany

Sibylle
Dr. Sibylle Loibl
Chief Executive Officer | Germany

"Prof. Dr. Sibylle Loibl is Chair of the German Breast Group and the Chief Executive Officer of the GBG Forschungs GmbH. Prof. Dr. Loibl is an associate professor of obstetrics and gynaecology at the Goethe University of Frankfurt. She gained a doctorate at the Ruprecht Karl University of Heidelberg and trained as a consultant in gynaecology and obstetrics at the women’s clinics of the university hospitals in Heidelberg and Frankfurt am Main. She devotes most of her time to clinical research within the German Breast Group and clinical work at the Centre for Haematology and Oncology, Bethanien in Frankfurt. Prof. Dr. Loibl has gained international renommée for her research in neoadjuvant breast cancer, breast cancer during pregnancy and breast cancer in young women. She established the Translational Research Group within the German Breast Group and has headed numerous research projects. In addition, Prof. Dr. Loibl has been involved in conducting and managing a significant number of national and international, practice-changing clinical trials. Prof. Dr. Loibl is author of more than 400 original and peer-reviewed articles and scientific papers; she has written numerous books and book chapters. She is an active member of many important national and international organizations, such as ASCO, ESMO, DKG and the AGO. She is involved in national and international guidelines for breast cancer, amongst them those for ESMO and ASCO. She was the first Co-Chair of the ESMO Breast Conference in Berlin and is an active faculty member of many international (ASCO, ESMO, SABCS) conferences."

Sessions by this speaker
Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Lectures by this speaker
Saturday, 2022-11-26
Optimal management of early HER2 positive Breast cancer - Supported by Roche

  08:50 - 09:10

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

Dr. Aydah Al Awadhi | United Arab Emirates

Aydah
Dr. Aydah Al Awadhi
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Aydah Al Awadhi is a Consultant Physician, Oncology Clinic at Tawam Hospital

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 3: Advanced Breast Cancer Session

  11:00 - 14:00

Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Lectures by this speaker
Saturday, 2022-11-26
Metastatic HER 2 low tumours- a new entity

  12:00 - 12:20

Saturday, 2022-11-26
Panel Discussion and Q&A

  13:00 - 13:10

Saturday, 2022-11-26
Optimal management of early HER2 positive Breast cancer - Supported by Roche

  08:50 - 09:10

  08:50 - 09:10

Tailoring adjuvant therapy in the molecular era

Dr. Zulfaqqar Ali | United Arab Emirates

Zulfaqqar
Dr. Zulfaqqar Ali
Oncologist/Haematologist | United Arab Emirates

Dr. JaffarAli trained at Columbia University/Roosevelt Hospital, New York and gained his Fellowship in Haematology and Oncology from New York Medical college, St. Vincent's Hospital. He is triple American board certified in Internal Medicine, Haematology and Medical Oncology. He practised in the USA as an Oncologist/Haematologist for more than 15 years prior to moving back to the UAE and has particular interests in breast cancer, cutting edge oncology treatments such as immunotherapy and genetic predisposition to cancers. He has been involved in clinical research in multiple cancers and has published and presented at the American Society of Clinical Oncology. He is a member of the American Society of Oncology.

Lectures by this speaker
Saturday, 2022-11-26
Tailoring adjuvant therapy in the molecular era

  09:10 - 09:30

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

  09:10 - 09:30

Breast Hypofractionation

Dr. Abdulla Alhasso | United Arab Emirates

Abdulla
Dr. Abdulla Alhasso
Consultant Clinical Oncologist | United Arab Emirates

Dr Abdulla Alhasso has joined the Beatson Oncology Centre as a Clinical Oncologist with a special interest in Breast cancer and Urological malignancies. He is actively involved in the provision of clinical services in Clyde area as well as South Glasgow. This involves direct clinical care through outpatient clinics including follow up, new patients and chemotherapy clinics. He is also involved in the medical training and supervision for the junior Oncology team and take an active role in medical research and clinical trials.

Lectures by this speaker
Saturday, 2022-11-26
Breast Hypofractionation

  09:30 - 09:50

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

  09:30 - 09:50

Early Breast Cancer and the Use of Abemacilcib to Prevent Recurrence in Patients with HR+, HER2- with High Risk of Recurrence - Supported by Lilly

Dr. Carlos Barrios | Brazil

Carlos
Dr. Carlos Barrios
Director and Principal Investigator | Brazil

Dr. Carlos Barrios is the Director and Principal Investigator of the Oncology Research Center at Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul since 1996, where he has participated in more than 300 clinical research trials during the past 15 years. He is Director of Clinical Research and Oncologist of the Oncoclínicas Group in Porto Alegre. He is Adjunct Assistant Professor of the William Harrington Latin American Program of the University of Miami School of Medicine. He has a strong interest in the development of international research collaboration and implementation of cooperative research infrastructures in Latin America.

Lectures by this speaker
Saturday, 2022-11-26
Abemaciclib-based therapy is the preferred first-line option

  11:20 - 11:30

Saturday, 2022-11-26
Early Breast Cancer and the Use of Abemacilcib to Prevent Recurrence in Patients with HR+, HER2- with High Risk of Recurrence - Supported by Lilly

  09:50 - 10:10

Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC

  11:30 - 11:40

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

Dr. Emad Dawoud | United Arab Emirates

Emad
Dr. Emad Dawoud
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Emad Dawoud is a Consultant Medical Oncologist in Oncology department at Tawam hospital UAE, and Assistant professor of clinical oncology in Al Azhar University Cairo, Egypt. Dr. Dawoud has been principal investigator and co- investigator for more than 50 clinical trials and abstract published per reviewed journals and he is a member of various associations such as ASCO, ESMO, ESTRO.

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Friday, 2022-11-25
Session 3: Gynaecological cancers

  11:20 - 14:00

Friday, 2022-11-25
Session 5: Gynaecological Cancers

  14:00 - 15:40

Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions

  14:00 - 16:50

Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Lectures by this speaker
Friday, 2022-11-25
Management of endometrial cancer in the molecular era

  15:40 - 16:00

Friday, 2022-11-25
Panel Discussion- Q&A

  15:00 - 15:20

Friday, 2022-11-25
Endometrial Cancer - Case Based Discussion

  12:00 - 12:30

Friday, 2022-11-25
Panel Discussion

  12:30 - 12:40

Friday, 2022-11-25
Panel Discussion- Q&A

  16:20 - 16:30

Saturday, 2022-11-26
Recent Advances in Systemic Therapy in Resected Lung Cancer - Supported by Roche

  14:40 - 15:00

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Sunday, 2022-11-27
Panel Discussion and Q & A

  12:40 - 13:00

Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen

  10:20 - 10:40

Sunday, 2022-11-27
Case Presentation Lung Cancer

  14:00 - 14:45

Sunday, 2022-11-27
Optimizing the 1st line treatment in mCRC - Supported by Merck

  12:00 - 12:20

Sunday, 2022-11-27
Panel Discussion and Q & A

  10:40 - 10:50

Saturday, 2022-11-26
Early Breast Cancer and the Use of Abemacilcib to Prevent Recurrence in Patients with HR+, HER2- with High Risk of Recurrence - Supported by Lilly

  09:50 - 10:10

  09:50 - 10:10

Panel Discussion and Q&A’s

Dr. Mohanad Diab | United Arab Emirates

Mohanad
Dr. Mohanad Diab
Consultant Medical Oncology | United Arab Emirates

Dr. Mohanad Diab is an established and highly skilled Consultant Medical Oncologist with over 12 years of experience in the field of Oncology. He pursued his MD in 2004 from Karolinska University, Sweden. He obtained his Certification in Bone Marrow Transplantation in 2008 from Oncology Hospital, Radiumhemmet. Dr. Diab spent the first half of his career in the hospitals of the West Gotland Region, Sweden, as a Consultant Medical Oncologist. In 2014, he relocated to UAE and served eight years as the Head of the Oncology Department in one of the leading private hospitals in Abu Dhabi before joining Burjeel Hospital, Abu Dhabi. He is well regarded for his active involvement in setting up a world-class oncology clinic and multi-disciplinary tumor board. His expertise is treating distinctive cancers through chemotherapy, targeted therapy, and immunotherapy. The conditions include brain cancer, oligodendroglioma, pancreatic cancer, colorectal cancer, meningioma, prostate cancer, mixed gliomas, lung cancer, ependymoma, metastatic cancer, oral cancer, primitive neuroectodermal tumor, breast cancer, cervical and ovarian cancer. He is an active contributor to the research & studies dedicated to the field of oncology and tumor diagnosis.

Sessions by this speaker
Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

Dr. Stephen Grobmyer | United Arab Emirates

Stephen
Dr. Stephen Grobmyer
Institute Chair of the Oncology | United Arab Emirates

"Dr. Stephen R. Grobmyer, MD, is the Institute Chair of the Oncology Institute at Cleveland Clinic Abu Dhabi. Prior to joining Cleveland Clinic Abu Dhabi, Dr. Grobmyer was Professor of Surgery, Section Head of Breast Surgery and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program at Cleveland Clinic Main Campus in Cleveland, Ohio. Dr. Grobmyer received his medical degree from the University of Texas Southwestern Medical School in Dallas, Texas and completed his residency in General Surgery at New York Hospital-Cornell Medical Center in New York. He completed a fellowship in Surgical Oncology at Memorial Sloan Kettering in 2004. Dr. Grobmyer™s innovative clinical care and research focuses on developing new approaches to prevent, diagnose and treat breast cancer. He has published over 170 peer-reviewed manuscripts, twenty book chapters and edited a textbook on innovative cancer therapies. Additionally, he has given over one hundred invited lectures nationally and internationally. "

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

Saturday, 2022-11-26
The Future of Breast Cancer Surgery

  08:30 - 08:50

Dr. Abdulla Alhasso | United Arab Emirates

Abdulla
Dr. Abdulla Alhasso
Consultant Clinical Oncologist | United Arab Emirates

Dr Abdulla Alhasso has joined the Beatson Oncology Centre as a Clinical Oncologist with a special interest in Breast cancer and Urological malignancies. He is actively involved in the provision of clinical services in Clyde area as well as South Glasgow. This involves direct clinical care through outpatient clinics including follow up, new patients and chemotherapy clinics. He is also involved in the medical training and supervision for the junior Oncology team and take an active role in medical research and clinical trials.

Lectures by this speaker
Saturday, 2022-11-26
Breast Hypofractionation

  09:30 - 09:50

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

Dr. Zulfaqqar Ali | United Arab Emirates

Zulfaqqar
Dr. Zulfaqqar Ali
Oncologist/Haematologist | United Arab Emirates

Dr. JaffarAli trained at Columbia University/Roosevelt Hospital, New York and gained his Fellowship in Haematology and Oncology from New York Medical college, St. Vincent's Hospital. He is triple American board certified in Internal Medicine, Haematology and Medical Oncology. He practised in the USA as an Oncologist/Haematologist for more than 15 years prior to moving back to the UAE and has particular interests in breast cancer, cutting edge oncology treatments such as immunotherapy and genetic predisposition to cancers. He has been involved in clinical research in multiple cancers and has published and presented at the American Society of Clinical Oncology. He is a member of the American Society of Oncology.

Lectures by this speaker
Saturday, 2022-11-26
Tailoring adjuvant therapy in the molecular era

  09:10 - 09:30

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

Dr. Sibylle Loibl | Germany

Sibylle
Dr. Sibylle Loibl
Chief Executive Officer | Germany

"Prof. Dr. Sibylle Loibl is Chair of the German Breast Group and the Chief Executive Officer of the GBG Forschungs GmbH. Prof. Dr. Loibl is an associate professor of obstetrics and gynaecology at the Goethe University of Frankfurt. She gained a doctorate at the Ruprecht Karl University of Heidelberg and trained as a consultant in gynaecology and obstetrics at the women’s clinics of the university hospitals in Heidelberg and Frankfurt am Main. She devotes most of her time to clinical research within the German Breast Group and clinical work at the Centre for Haematology and Oncology, Bethanien in Frankfurt. Prof. Dr. Loibl has gained international renommée for her research in neoadjuvant breast cancer, breast cancer during pregnancy and breast cancer in young women. She established the Translational Research Group within the German Breast Group and has headed numerous research projects. In addition, Prof. Dr. Loibl has been involved in conducting and managing a significant number of national and international, practice-changing clinical trials. Prof. Dr. Loibl is author of more than 400 original and peer-reviewed articles and scientific papers; she has written numerous books and book chapters. She is an active member of many important national and international organizations, such as ASCO, ESMO, DKG and the AGO. She is involved in national and international guidelines for breast cancer, amongst them those for ESMO and ASCO. She was the first Co-Chair of the ESMO Breast Conference in Berlin and is an active faculty member of many international (ASCO, ESMO, SABCS) conferences."

Sessions by this speaker
Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Lectures by this speaker
Saturday, 2022-11-26
Optimal management of early HER2 positive Breast cancer - Supported by Roche

  08:50 - 09:10

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

Dr. Carlos Barrios | Brazil

Carlos
Dr. Carlos Barrios
Director and Principal Investigator | Brazil

Dr. Carlos Barrios is the Director and Principal Investigator of the Oncology Research Center at Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul since 1996, where he has participated in more than 300 clinical research trials during the past 15 years. He is Director of Clinical Research and Oncologist of the Oncoclínicas Group in Porto Alegre. He is Adjunct Assistant Professor of the William Harrington Latin American Program of the University of Miami School of Medicine. He has a strong interest in the development of international research collaboration and implementation of cooperative research infrastructures in Latin America.

Lectures by this speaker
Saturday, 2022-11-26
Abemaciclib-based therapy is the preferred first-line option

  11:20 - 11:30

Saturday, 2022-11-26
Early Breast Cancer and the Use of Abemacilcib to Prevent Recurrence in Patients with HR+, HER2- with High Risk of Recurrence - Supported by Lilly

  09:50 - 10:10

Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC

  11:30 - 11:40

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

Dr. Mouza Mohd Al Ameri | United Arab Emirates

Mouza
Dr. Mouza Mohd Al Ameri
Consultant Physician, Oncology – Breast Care Center (Dep) | United Arab Emirates

Mouza Al Ameri is a breast onco-plastic surgeon and assistant professor of surgery in UAE University and Tawam Hospital. She is passionate about breast cancer research, empowering breast cancer survivors and disseminate breast cancer awareness among society members.

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

Saturday, 2022-11-26
Welcome Note

  08:30 - 08:31

Dr. Nouri Bennini | United Arab Emirates

Nouri
Dr. Nouri Bennini
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr.Nouri Bennini is a Consultant Physician, Oncology Clinic at Tawam Hospital.

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Sunday, 2022-11-27
Session 5: Gastrointestinal Session

  14:00 - 16:40

Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions

  14:00 - 16:50

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

Saturday, 2022-11-26
Beyond Covid 19 Vaccination : Evusheld (Tixagevimab and Cilgevimab ) for the Prevention and Treatment of Covid 19 among the High Risk Patients - Supported by AstraZeneca

  15:10 - 15:30

Sunday, 2022-11-27
Panel Discussion and Q&A’s

  15:20 - 15:30

Sunday, 2022-11-27
Dual Immunotherapy Approach in 1L RCC Treatment - Supported by BMS

  11:20 - 11:50

Sunday, 2022-11-27
Case Presentation Breast Cancer

  14:45 - 15:30

Sunday, 2022-11-27
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly

  12:20 - 12:40

  10:10 - 10:30

COFFEE BREAK

  10:30 - 11:00

Session 3: Advanced Breast Cancer Session
Chairperson:

Dr. Aladdin Marraoui | United Arab Emirates

Aladdin
Dr. Aladdin Marraoui
Consultant and Chief of Medical Oncology | United Arab Emirates

Dr. Maarraoui is Consultant and Chief of Hematology/Oncology at Gulf International Cancer Center in Abu Dhabi and Clinical Professor at Gulf Medical University, UAE. He previously served as Chief of Hematology/Oncology at Mafraq Hospital for 14 years. He graduated from Faculty of Medicine at Aleppo University/Syria. He did his Internal Medicine residency at Christ Hospital and Medical Center in Chicago, and his Hematology/Oncology fellowship at the University of Colorado Health Science Center in Denver, Colorado. He is American Board Certified and recertified in Internal medicine in 1992, 2002 and 2012, in Medical Oncology in 1999,2009 and 2019 and in Hematology in 1999, 2009 and 2019. Dr. Maarraoui authored and co-authored several abstracts and articles on Breast Cancer, Colon Cancer, Thyroid Cancer, lung cancer and Lymphoma focusing on these diseases in UAE.

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -


Chairperson:

Dr. Ernest Johan Luiten | United Arab Emirates

Ernest
Dr. Ernest Johan Luiten
Chief of Breast Cancer Center | United Arab Emirates

Chief of Breast Cancer Center- Tawam Hospital

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -


Chairperson:

Dr. Aydah Al Awadhi | United Arab Emirates

Aydah
Dr. Aydah Al Awadhi
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Aydah Al Awadhi is a Consultant Physician, Oncology Clinic at Tawam Hospital

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -


Speaker:

Dr. Hassan Ghazal | United Arab Emirates

Hassan
Dr. Hassan Ghazal
Consultant Medical Oncologist & Consultant Clinical Hematologist | United Arab Emirates

"Dr Hassan Ghazal is an American board-certified Consultant Medical Oncologist and a Consultant Clinical hematologist offering more than 3 decades of clinical experience. Dr Hassan Ghazal, after doing his basic medical education in American University of Beirut, moved to US for his residency program in Internal Medicine at Sinai Hospital of Baltimore, MD. In 1992, completing the residency program, Dr Hassan Ghazal joined in George Washington university Medical Center for his fellowship in Medical Oncology and completed the same in 1995. He continued in George Washington University Medical Center for another 2 years and obtained his senior fellowship in bone marrow transplantation in the year 1997. He got his US board certification in Internal Medicine, Medical Oncology and in Hematology in the year 1992, 1995,1996 respectively. Except his association with CMC for the preceding 3 years, all his clinical practices were in US in various capacities including Director, Kentucky Cancer Clinic and Staff Oncologist/ Hematologist at Hazard Appalachian Regional Medical Center. Dr Hassan Ghazal is a member of various clinical societies such as American College of Physicians, American Society of Haematology, American Society of Clinical Oncology, European Society of Medical Oncology etc. Dr Hassan Ghazal has got many publications and abstracts in his credit, in peer reviewed journals, and there are many international recognitions and accolades in his name. He has been involved in numerous clinical trials, nearly 100, in the US, serving as Principal Investigator, for over 25 years, and enrolled hundreds of patients in these trials."

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -


Speaker:

Prof. Michail Ignatiadis | Belgium

Michail
Prof. Michail Ignatiadis
Senior Attending Physician | Belgium

"Michail Ignatiadis, MD PhD is senior attending physician at the Medical Oncology Department, Jules Bordet Institute (IJB) and associate professor at the Université Libre de Bruxelles, Belgium. Since January 2021, he is the chair of the breast cancer group of the EORTC. He is also leading the Academic Trials Promoting Team (ATPT) and he is member of the Executive and Research Boards of IJB since October 2016. He participates in developing the IJB research strategy. He works with his team and members of the Executive and Research Boards to promote high-quality, innovative, academic research at the institutional level. From June 2018 to January 2021, he served in the Board of Directors of the EORTC as the chair of the clinical research division. He has been involved in many investigator-initiated trials (IITs) sponsored by IJB at different stages of their development. He has been member of the Independent Data Monitoring Committees for international trials and study chair of several IITs. He served as IJB principal investigator for many industry sponsored trials. Currently, he is the study chair of the Alexandra/Impassion030 registration trial. He is particularly interested in drug and biomarker development in breast cancer. His work in the field of blood-based biomarkers is widely recognised at the international level. He has published more than 100 articles in peer reviewed journals including several papers in high impact factor journals such as Journal of Clinical Oncology, Nature Reviews Clinical Oncology, JAMA Oncology, Journal of National Cancer Institute, Lancet Oncology as well as several book chapters; he is editor of a book on minimal residual disease. He has served as reviewer for several national and international organisations including the French National Cancer Institute (INCA), the Technology Foundation STW in the Netherlands, the Marie-Curie Fellowships, the European Research Council (ERC) and the Innovative Medicines Initiative (IMI). He has served as Chair or Co-Chair of symposia in high visibility international conferences, organised by ESMO, ECCO and ASCO. He has served as faculty in the prestigious workshop ‘Methods in Clinical Cancer Research’ every year from 2014 until 2019. He has obtained independent research funding over the last 6 years."

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -


Speaker:

Dr. Meteb Foheidi | Saudi Arabia

Meteb
Dr. Meteb Foheidi
Medical Oncology Consultant | Saudi Arabia

Dr. Meteb Foheidi is a medical oncology consultant at Princess Noorah Oncology Center, National Guard Health Affairs, Jeddah, Asistant Professor & Medical Oncology Block Cordinator at King Saud Bin Abdulaziz University for Health and Science – Jeddah and Western Oncology Group Director, Saudi Oncology Society.

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -


  11:00 - 14:00

Ribociclib-based therapy is the preferred first-line option

Prof. Michail Ignatiadis | Belgium

Michail
Prof. Michail Ignatiadis
Senior Attending Physician | Belgium

"Michail Ignatiadis, MD PhD is senior attending physician at the Medical Oncology Department, Jules Bordet Institute (IJB) and associate professor at the Université Libre de Bruxelles, Belgium. Since January 2021, he is the chair of the breast cancer group of the EORTC. He is also leading the Academic Trials Promoting Team (ATPT) and he is member of the Executive and Research Boards of IJB since October 2016. He participates in developing the IJB research strategy. He works with his team and members of the Executive and Research Boards to promote high-quality, innovative, academic research at the institutional level. From June 2018 to January 2021, he served in the Board of Directors of the EORTC as the chair of the clinical research division. He has been involved in many investigator-initiated trials (IITs) sponsored by IJB at different stages of their development. He has been member of the Independent Data Monitoring Committees for international trials and study chair of several IITs. He served as IJB principal investigator for many industry sponsored trials. Currently, he is the study chair of the Alexandra/Impassion030 registration trial. He is particularly interested in drug and biomarker development in breast cancer. His work in the field of blood-based biomarkers is widely recognised at the international level. He has published more than 100 articles in peer reviewed journals including several papers in high impact factor journals such as Journal of Clinical Oncology, Nature Reviews Clinical Oncology, JAMA Oncology, Journal of National Cancer Institute, Lancet Oncology as well as several book chapters; he is editor of a book on minimal residual disease. He has served as reviewer for several national and international organisations including the French National Cancer Institute (INCA), the Technology Foundation STW in the Netherlands, the Marie-Curie Fellowships, the European Research Council (ERC) and the Innovative Medicines Initiative (IMI). He has served as Chair or Co-Chair of symposia in high visibility international conferences, organised by ESMO, ECCO and ASCO. He has served as faculty in the prestigious workshop ‘Methods in Clinical Cancer Research’ every year from 2014 until 2019. He has obtained independent research funding over the last 6 years."

Sessions by this speaker
Saturday, 2022-11-26
Session 3: Advanced Breast Cancer Session

  11:00 - 14:00

Lectures by this speaker
Saturday, 2022-11-26
Ribociclib-based therapy is the preferred first-line option

  11:00 - 11:10

Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC

  11:30 - 11:40

Saturday, 2022-11-26
Improving Survival & HRQOL Outcomes in HR+ HER2- Advanced Breast Cancer - Supported by Novartis

  12:40 - 13:00

Saturday, 2022-11-26
Panel Discussion and Q&A

  13:00 - 13:10

  11:00 - 11:10

Palbociclib-based therapy is the preferred first-line option

Dr. Anwar Al Nouri | Kuwait

Anwar
Dr. Anwar Al Nouri
Oncologist | Kuwait

Dr. Anwar Al Nouri is an oncologist at Kuwait Cancer Control Centre

Lectures by this speaker
Saturday, 2022-11-26
Palbociclib-based therapy is the preferred first-line option

  11:10 - 11:20

Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC

  11:30 - 11:40

Sunday, 2022-11-27
Case Presentation Breast Cancer

  14:45 - 15:30

  11:10 - 11:20

Abemaciclib-based therapy is the preferred first-line option

Dr. Carlos Barrios | Brazil

Carlos
Dr. Carlos Barrios
Director and Principal Investigator | Brazil

Dr. Carlos Barrios is the Director and Principal Investigator of the Oncology Research Center at Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul since 1996, where he has participated in more than 300 clinical research trials during the past 15 years. He is Director of Clinical Research and Oncologist of the Oncoclínicas Group in Porto Alegre. He is Adjunct Assistant Professor of the William Harrington Latin American Program of the University of Miami School of Medicine. He has a strong interest in the development of international research collaboration and implementation of cooperative research infrastructures in Latin America.

Lectures by this speaker
Saturday, 2022-11-26
Abemaciclib-based therapy is the preferred first-line option

  11:20 - 11:30

Saturday, 2022-11-26
Early Breast Cancer and the Use of Abemacilcib to Prevent Recurrence in Patients with HR+, HER2- with High Risk of Recurrence - Supported by Lilly

  09:50 - 10:10

Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC

  11:30 - 11:40

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

  11:20 - 11:30

Panel discussion and Q&A’s for first line HR-positive ABC

Dr. Hassan Ghazal | United Arab Emirates

Hassan
Dr. Hassan Ghazal
Consultant Medical Oncologist & Consultant Clinical Hematologist | United Arab Emirates

"Dr Hassan Ghazal is an American board-certified Consultant Medical Oncologist and a Consultant Clinical hematologist offering more than 3 decades of clinical experience. Dr Hassan Ghazal, after doing his basic medical education in American University of Beirut, moved to US for his residency program in Internal Medicine at Sinai Hospital of Baltimore, MD. In 1992, completing the residency program, Dr Hassan Ghazal joined in George Washington university Medical Center for his fellowship in Medical Oncology and completed the same in 1995. He continued in George Washington University Medical Center for another 2 years and obtained his senior fellowship in bone marrow transplantation in the year 1997. He got his US board certification in Internal Medicine, Medical Oncology and in Hematology in the year 1992, 1995,1996 respectively. Except his association with CMC for the preceding 3 years, all his clinical practices were in US in various capacities including Director, Kentucky Cancer Clinic and Staff Oncologist/ Hematologist at Hazard Appalachian Regional Medical Center. Dr Hassan Ghazal is a member of various clinical societies such as American College of Physicians, American Society of Haematology, American Society of Clinical Oncology, European Society of Medical Oncology etc. Dr Hassan Ghazal has got many publications and abstracts in his credit, in peer reviewed journals, and there are many international recognitions and accolades in his name. He has been involved in numerous clinical trials, nearly 100, in the US, serving as Principal Investigator, for over 25 years, and enrolled hundreds of patients in these trials."

Sessions by this speaker
Saturday, 2022-11-26
Session 3: Advanced Breast Cancer Session

  11:00 - 14:00

Sunday, 2022-11-27
Session 3: Gastrointestinal Session

  11:00 - 14:00

Sunday, 2022-11-27
Session 5: Gastrointestinal Session

  14:00 - 16:40

Lectures by this speaker
Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC

  11:30 - 11:40

Sunday, 2022-11-27
Panel Discussion and Q & A

  12:40 - 13:00

Sunday, 2022-11-27
Panel Discussion and Q&A’s

  15:20 - 15:30

Dr. Aladdin Marraoui | United Arab Emirates

Aladdin
Dr. Aladdin Marraoui
Consultant and Chief of Medical Oncology | United Arab Emirates

Dr. Maarraoui is Consultant and Chief of Hematology/Oncology at Gulf International Cancer Center in Abu Dhabi and Clinical Professor at Gulf Medical University, UAE. He previously served as Chief of Hematology/Oncology at Mafraq Hospital for 14 years. He graduated from Faculty of Medicine at Aleppo University/Syria. He did his Internal Medicine residency at Christ Hospital and Medical Center in Chicago, and his Hematology/Oncology fellowship at the University of Colorado Health Science Center in Denver, Colorado. He is American Board Certified and recertified in Internal medicine in 1992, 2002 and 2012, in Medical Oncology in 1999,2009 and 2019 and in Hematology in 1999, 2009 and 2019. Dr. Maarraoui authored and co-authored several abstracts and articles on Breast Cancer, Colon Cancer, Thyroid Cancer, lung cancer and Lymphoma focusing on these diseases in UAE.

Sessions by this speaker
Saturday, 2022-11-26
Session 3: Advanced Breast Cancer Session

  11:00 - 14:00

Lectures by this speaker
Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC

  11:30 - 11:40

Prof. Michail Ignatiadis | Belgium

Michail
Prof. Michail Ignatiadis
Senior Attending Physician | Belgium

"Michail Ignatiadis, MD PhD is senior attending physician at the Medical Oncology Department, Jules Bordet Institute (IJB) and associate professor at the Université Libre de Bruxelles, Belgium. Since January 2021, he is the chair of the breast cancer group of the EORTC. He is also leading the Academic Trials Promoting Team (ATPT) and he is member of the Executive and Research Boards of IJB since October 2016. He participates in developing the IJB research strategy. He works with his team and members of the Executive and Research Boards to promote high-quality, innovative, academic research at the institutional level. From June 2018 to January 2021, he served in the Board of Directors of the EORTC as the chair of the clinical research division. He has been involved in many investigator-initiated trials (IITs) sponsored by IJB at different stages of their development. He has been member of the Independent Data Monitoring Committees for international trials and study chair of several IITs. He served as IJB principal investigator for many industry sponsored trials. Currently, he is the study chair of the Alexandra/Impassion030 registration trial. He is particularly interested in drug and biomarker development in breast cancer. His work in the field of blood-based biomarkers is widely recognised at the international level. He has published more than 100 articles in peer reviewed journals including several papers in high impact factor journals such as Journal of Clinical Oncology, Nature Reviews Clinical Oncology, JAMA Oncology, Journal of National Cancer Institute, Lancet Oncology as well as several book chapters; he is editor of a book on minimal residual disease. He has served as reviewer for several national and international organisations including the French National Cancer Institute (INCA), the Technology Foundation STW in the Netherlands, the Marie-Curie Fellowships, the European Research Council (ERC) and the Innovative Medicines Initiative (IMI). He has served as Chair or Co-Chair of symposia in high visibility international conferences, organised by ESMO, ECCO and ASCO. He has served as faculty in the prestigious workshop ‘Methods in Clinical Cancer Research’ every year from 2014 until 2019. He has obtained independent research funding over the last 6 years."

Sessions by this speaker
Saturday, 2022-11-26
Session 3: Advanced Breast Cancer Session

  11:00 - 14:00

Lectures by this speaker
Saturday, 2022-11-26
Ribociclib-based therapy is the preferred first-line option

  11:00 - 11:10

Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC

  11:30 - 11:40

Saturday, 2022-11-26
Improving Survival & HRQOL Outcomes in HR+ HER2- Advanced Breast Cancer - Supported by Novartis

  12:40 - 13:00

Saturday, 2022-11-26
Panel Discussion and Q&A

  13:00 - 13:10

Dr. Anwar Al Nouri | Kuwait

Anwar
Dr. Anwar Al Nouri
Oncologist | Kuwait

Dr. Anwar Al Nouri is an oncologist at Kuwait Cancer Control Centre

Lectures by this speaker
Saturday, 2022-11-26
Palbociclib-based therapy is the preferred first-line option

  11:10 - 11:20

Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC

  11:30 - 11:40

Sunday, 2022-11-27
Case Presentation Breast Cancer

  14:45 - 15:30

Dr. Carlos Barrios | Brazil

Carlos
Dr. Carlos Barrios
Director and Principal Investigator | Brazil

Dr. Carlos Barrios is the Director and Principal Investigator of the Oncology Research Center at Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul since 1996, where he has participated in more than 300 clinical research trials during the past 15 years. He is Director of Clinical Research and Oncologist of the Oncoclínicas Group in Porto Alegre. He is Adjunct Assistant Professor of the William Harrington Latin American Program of the University of Miami School of Medicine. He has a strong interest in the development of international research collaboration and implementation of cooperative research infrastructures in Latin America.

Lectures by this speaker
Saturday, 2022-11-26
Abemaciclib-based therapy is the preferred first-line option

  11:20 - 11:30

Saturday, 2022-11-26
Early Breast Cancer and the Use of Abemacilcib to Prevent Recurrence in Patients with HR+, HER2- with High Risk of Recurrence - Supported by Lilly

  09:50 - 10:10

Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC

  11:30 - 11:40

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

  11:30 - 11:40

Changing paradigm for the treatment of HER2 positive Metastatic Breast cancer

Dr. Meteb Foheidi | Saudi Arabia

Meteb
Dr. Meteb Foheidi
Medical Oncology Consultant | Saudi Arabia

Dr. Meteb Foheidi is a medical oncology consultant at Princess Noorah Oncology Center, National Guard Health Affairs, Jeddah, Asistant Professor & Medical Oncology Block Cordinator at King Saud Bin Abdulaziz University for Health and Science – Jeddah and Western Oncology Group Director, Saudi Oncology Society.

Sessions by this speaker
Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Saturday, 2022-11-26
Session 3: Advanced Breast Cancer Session

  11:00 - 14:00

Lectures by this speaker
Saturday, 2022-11-26
Changing paradigm for the treatment of HER2 positive Metastatic Breast cancer

  11:40 - 12:00

Saturday, 2022-11-26
Panel Discussion and Q&A

  13:00 - 13:10

  11:40 - 12:00

Metastatic HER 2 low tumours- a new entity

Dr. Aydah Al Awadhi | United Arab Emirates

Aydah
Dr. Aydah Al Awadhi
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Aydah Al Awadhi is a Consultant Physician, Oncology Clinic at Tawam Hospital

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 3: Advanced Breast Cancer Session

  11:00 - 14:00

Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Lectures by this speaker
Saturday, 2022-11-26
Metastatic HER 2 low tumours- a new entity

  12:00 - 12:20

Saturday, 2022-11-26
Panel Discussion and Q&A

  13:00 - 13:10

Saturday, 2022-11-26
Optimal management of early HER2 positive Breast cancer - Supported by Roche

  08:50 - 09:10

  12:00 - 12:20

Real world effectiveness data for MBC patients – Supported by Pfizer

Dr. Diaeddine Trad | United Arab Emirates

Diaeddine
Dr. Diaeddine Trad
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Diaeddine Trad is a Consultant of Medical Oncology, at Tawam Hospital, in Al Ain, UAE. He is a member of the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). He is an investigator in several ongoing clinical trials. Dr. Trad is certified as a specialist in internal medicine, hematology and oncology by the Lebanese Ministry of Health. His research interests include; non-small cell lung adenocarcinoma and locally advanced breast cancer. Dr. Trad was a speaker in many international conferences and forums.

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 5: Lung Cancer Session

  14:00 - 15:40

Sunday, 2022-11-27
Session 3: Gastrointestinal Session

  11:00 - 14:00

Saturday, 2022-11-26
Session 7: Lung Cancer Session

  15:40 - 17:30

Lectures by this speaker
Saturday, 2022-11-26
Real world effectiveness data for MBC patients – Supported by Pfizer

  12:20 - 12:40

Saturday, 2022-11-26
Panel Discussion and Q&A

  13:00 - 13:10

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Saturday, 2022-11-26
Closing Remarks

  17:10 - 17:20

Sunday, 2022-11-27
Panel Discussion and Q & A

  12:40 - 13:00

Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions

  16:00 - 16:40

Sunday, 2022-11-27
Meeting Close

  16:35 - 16:40

Sunday, 2022-11-27
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly

  12:20 - 12:40

  12:20 - 12:40

Improving Survival & HRQOL Outcomes in HR+ HER2- Advanced Breast Cancer - Supported by Novartis

Prof. Michail Ignatiadis | Belgium

Michail
Prof. Michail Ignatiadis
Senior Attending Physician | Belgium

"Michail Ignatiadis, MD PhD is senior attending physician at the Medical Oncology Department, Jules Bordet Institute (IJB) and associate professor at the Université Libre de Bruxelles, Belgium. Since January 2021, he is the chair of the breast cancer group of the EORTC. He is also leading the Academic Trials Promoting Team (ATPT) and he is member of the Executive and Research Boards of IJB since October 2016. He participates in developing the IJB research strategy. He works with his team and members of the Executive and Research Boards to promote high-quality, innovative, academic research at the institutional level. From June 2018 to January 2021, he served in the Board of Directors of the EORTC as the chair of the clinical research division. He has been involved in many investigator-initiated trials (IITs) sponsored by IJB at different stages of their development. He has been member of the Independent Data Monitoring Committees for international trials and study chair of several IITs. He served as IJB principal investigator for many industry sponsored trials. Currently, he is the study chair of the Alexandra/Impassion030 registration trial. He is particularly interested in drug and biomarker development in breast cancer. His work in the field of blood-based biomarkers is widely recognised at the international level. He has published more than 100 articles in peer reviewed journals including several papers in high impact factor journals such as Journal of Clinical Oncology, Nature Reviews Clinical Oncology, JAMA Oncology, Journal of National Cancer Institute, Lancet Oncology as well as several book chapters; he is editor of a book on minimal residual disease. He has served as reviewer for several national and international organisations including the French National Cancer Institute (INCA), the Technology Foundation STW in the Netherlands, the Marie-Curie Fellowships, the European Research Council (ERC) and the Innovative Medicines Initiative (IMI). He has served as Chair or Co-Chair of symposia in high visibility international conferences, organised by ESMO, ECCO and ASCO. He has served as faculty in the prestigious workshop ‘Methods in Clinical Cancer Research’ every year from 2014 until 2019. He has obtained independent research funding over the last 6 years."

Sessions by this speaker
Saturday, 2022-11-26
Session 3: Advanced Breast Cancer Session

  11:00 - 14:00

Lectures by this speaker
Saturday, 2022-11-26
Ribociclib-based therapy is the preferred first-line option

  11:00 - 11:10

Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC

  11:30 - 11:40

Saturday, 2022-11-26
Improving Survival & HRQOL Outcomes in HR+ HER2- Advanced Breast Cancer - Supported by Novartis

  12:40 - 13:00

Saturday, 2022-11-26
Panel Discussion and Q&A

  13:00 - 13:10

  12:40 - 13:00

Panel Discussion and Q&A

Dr. Faisal Al Terkait | Kuwait

Faisal Al
Dr. Faisal Al Terkait
Medical Oncologist | Kuwait

"Medical oncologist in Kuwait cancer control center from 2012, Head of breast unit from 2017 to 2021, inaugurated the first medical oncology departments outside kccc in Kuwait. Currently Head of Medical oncology department at Jaber al-Ahmad hospital in Kuwait. MRCP UK. MBBS UK. CCST ONCOLOGY UK "

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A

  13:00 - 13:10

Dr. Meteb Foheidi | Saudi Arabia

Meteb
Dr. Meteb Foheidi
Medical Oncology Consultant | Saudi Arabia

Dr. Meteb Foheidi is a medical oncology consultant at Princess Noorah Oncology Center, National Guard Health Affairs, Jeddah, Asistant Professor & Medical Oncology Block Cordinator at King Saud Bin Abdulaziz University for Health and Science – Jeddah and Western Oncology Group Director, Saudi Oncology Society.

Sessions by this speaker
Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Saturday, 2022-11-26
Session 3: Advanced Breast Cancer Session

  11:00 - 14:00

Lectures by this speaker
Saturday, 2022-11-26
Changing paradigm for the treatment of HER2 positive Metastatic Breast cancer

  11:40 - 12:00

Saturday, 2022-11-26
Panel Discussion and Q&A

  13:00 - 13:10

Prof. Michail Ignatiadis | Belgium

Michail
Prof. Michail Ignatiadis
Senior Attending Physician | Belgium

"Michail Ignatiadis, MD PhD is senior attending physician at the Medical Oncology Department, Jules Bordet Institute (IJB) and associate professor at the Université Libre de Bruxelles, Belgium. Since January 2021, he is the chair of the breast cancer group of the EORTC. He is also leading the Academic Trials Promoting Team (ATPT) and he is member of the Executive and Research Boards of IJB since October 2016. He participates in developing the IJB research strategy. He works with his team and members of the Executive and Research Boards to promote high-quality, innovative, academic research at the institutional level. From June 2018 to January 2021, he served in the Board of Directors of the EORTC as the chair of the clinical research division. He has been involved in many investigator-initiated trials (IITs) sponsored by IJB at different stages of their development. He has been member of the Independent Data Monitoring Committees for international trials and study chair of several IITs. He served as IJB principal investigator for many industry sponsored trials. Currently, he is the study chair of the Alexandra/Impassion030 registration trial. He is particularly interested in drug and biomarker development in breast cancer. His work in the field of blood-based biomarkers is widely recognised at the international level. He has published more than 100 articles in peer reviewed journals including several papers in high impact factor journals such as Journal of Clinical Oncology, Nature Reviews Clinical Oncology, JAMA Oncology, Journal of National Cancer Institute, Lancet Oncology as well as several book chapters; he is editor of a book on minimal residual disease. He has served as reviewer for several national and international organisations including the French National Cancer Institute (INCA), the Technology Foundation STW in the Netherlands, the Marie-Curie Fellowships, the European Research Council (ERC) and the Innovative Medicines Initiative (IMI). He has served as Chair or Co-Chair of symposia in high visibility international conferences, organised by ESMO, ECCO and ASCO. He has served as faculty in the prestigious workshop ‘Methods in Clinical Cancer Research’ every year from 2014 until 2019. He has obtained independent research funding over the last 6 years."

Sessions by this speaker
Saturday, 2022-11-26
Session 3: Advanced Breast Cancer Session

  11:00 - 14:00

Lectures by this speaker
Saturday, 2022-11-26
Ribociclib-based therapy is the preferred first-line option

  11:00 - 11:10

Saturday, 2022-11-26
Panel discussion and Q&A’s for first line HR-positive ABC

  11:30 - 11:40

Saturday, 2022-11-26
Improving Survival & HRQOL Outcomes in HR+ HER2- Advanced Breast Cancer - Supported by Novartis

  12:40 - 13:00

Saturday, 2022-11-26
Panel Discussion and Q&A

  13:00 - 13:10

Dr. Aydah Al Awadhi | United Arab Emirates

Aydah
Dr. Aydah Al Awadhi
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Aydah Al Awadhi is a Consultant Physician, Oncology Clinic at Tawam Hospital

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 3: Advanced Breast Cancer Session

  11:00 - 14:00

Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Lectures by this speaker
Saturday, 2022-11-26
Metastatic HER 2 low tumours- a new entity

  12:00 - 12:20

Saturday, 2022-11-26
Panel Discussion and Q&A

  13:00 - 13:10

Saturday, 2022-11-26
Optimal management of early HER2 positive Breast cancer - Supported by Roche

  08:50 - 09:10

Dr. Diaeddine Trad | United Arab Emirates

Diaeddine
Dr. Diaeddine Trad
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Diaeddine Trad is a Consultant of Medical Oncology, at Tawam Hospital, in Al Ain, UAE. He is a member of the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). He is an investigator in several ongoing clinical trials. Dr. Trad is certified as a specialist in internal medicine, hematology and oncology by the Lebanese Ministry of Health. His research interests include; non-small cell lung adenocarcinoma and locally advanced breast cancer. Dr. Trad was a speaker in many international conferences and forums.

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 5: Lung Cancer Session

  14:00 - 15:40

Sunday, 2022-11-27
Session 3: Gastrointestinal Session

  11:00 - 14:00

Saturday, 2022-11-26
Session 7: Lung Cancer Session

  15:40 - 17:30

Lectures by this speaker
Saturday, 2022-11-26
Real world effectiveness data for MBC patients – Supported by Pfizer

  12:20 - 12:40

Saturday, 2022-11-26
Panel Discussion and Q&A

  13:00 - 13:10

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Saturday, 2022-11-26
Closing Remarks

  17:10 - 17:20

Sunday, 2022-11-27
Panel Discussion and Q & A

  12:40 - 13:00

Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions

  16:00 - 16:40

Sunday, 2022-11-27
Meeting Close

  16:35 - 16:40

Sunday, 2022-11-27
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly

  12:20 - 12:40

  13:00 - 13:10

LUNCH BREAK

  13:10 - 14:00

Session 5: Lung Cancer Session
Chairperson:

Dr. Maroun Khoury | United Arab Emirates

Maroun
Dr. Maroun Khoury
Consultant Oncologist/ Hematologist | United Arab Emirates

Assistant Professor Doctor Maroun El Khoury Consultant Oncologist/ Hematologist at American Hospital in Dubai 9/2010-Present. Mayo Clinic Network (Jci Accredited), Director Of Cancer Care Center, President of Medical Staff: 2018-2020. Chairperson Scientific Committee, Emirates Oncology Society: 2018-2020 .7/2006-8/2010: Private Practice In The Us/Iowa: Medical Director Of Oncology And Hematology Services And Chief Of Medicine At Great River Health System .7/2006-2010: Hospice Medical Co-Director .Epec (Education In Palliative And End-Of-Life Care) Trainer.

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -


Chairperson:

Dr. Aref Chehal | United Arab Emirates

Aref
Dr. Aref Chehal
Adjunct Clinical Associate Professor of Medicine | United Arab Emirates

Dr. Chehal is an Adjunct Clinical Associate Professor of Medicine, Gulf Medical University (GMU), Ajman, UAE Dr. Chehal is an Adjunct Clinical Associate Professor of Medicine, Khalifa University (KU), Abu Dhabi, UAE Dr. Chehal graduated from the college of Medicine at Baghdad University/Iraq (MBChB) in 1996. He did his Internal Medicine residency at Makassed General Hospital (Affiliated with American University of Beirut), Lebanon, between 1997 and 2000. He did his Hematology/Oncology fellowship at the American University of Beirut (AUBMC), Lebanon, between 2000 and 2003 (Lebanese Board). He obtained Fellowship of the American College of Physician (FACP) in 2013. He obtained the European Certification of Medical Oncology (ECMO) in 2009 and Re-certification in 2014 and 2021. Dr. Chehal is a member of many national and international societies including ASCO, ESMO, EHA,….. He had an important role in Tumor registry in Lebanon in 2002. Dr. Chehal acted as chairperson, moderator, advisor, and member of scientific committee in many local and international congresses. Dr. Chehal has 27 published articles in peer reviewed international journals; he is the first author on 9 of them, in addition to 31 abstracts. He joined Mafraq hospital From May 2006 until December 2019. He served as head of Hematology Oncology division at Mafraq Hospital from December 2018 till December 2019 His main interests are Lung cancer, Breast Cancer, GI malignancies and Lymphoma.

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -


Chairperson:

Dr. Diaeddine Trad | United Arab Emirates

Diaeddine
Dr. Diaeddine Trad
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Diaeddine Trad is a Consultant of Medical Oncology, at Tawam Hospital, in Al Ain, UAE. He is a member of the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). He is an investigator in several ongoing clinical trials. Dr. Trad is certified as a specialist in internal medicine, hematology and oncology by the Lebanese Ministry of Health. His research interests include; non-small cell lung adenocarcinoma and locally advanced breast cancer. Dr. Trad was a speaker in many international conferences and forums.

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -


  14:00 - 15:40

Surgical Advances in NSCLC Management

Dr. Norberto Santana | United Arab Emirates

Norberto
Dr. Norberto Santana
Chair of Thoracic Surgery | United Arab Emirates

Dr. Norberto is an experienced surgeon with a strong background in minimally invasive surgery, lung transplantation, hospital management, team leader, education, and translational research. He has recently joined SSMC-Mayo Clinic in Abu Dhabi as Chair of Thoracic Surgery. Previously, he was the Head of Thoracic Surgery and Lung Transplantation at one of the most prestigious hospitals in the Middle East, King Faisal Specialist Hospital & Research Center, ranked 76 worldwide. Here, he has set for the first time in the Kingdom of Saudi Arabia and the Middle East, the uniportal video-assisted thoracic surgery (VATS) program for lung resections, mediastinum, foregut, and pleural diseases, the uniportal VATS lung anatomical segmentectomy program in patients with lung cancer or centrally located lung metastasis to prevent the lobectomy, uniportal VATS decortication program to avoid the thoracotomy in patients with empyema, and the robotic thoracic surgery (RATS) program together with other novel programs such as: VATS cytoreductive surgery plus unidirectional hyperthermic intrathoracic chemotherapy (HITHOC) for patients with malignant pleural diseases (mesothelioma, thymoma, etc.), the introduction of ECMO and CBP for major airway and lung tumor resections, endoscopic closure of bronchopleural fistula, 3D reconstruction for personalized surgical treatment through the planning of lung sparing surgery, minimally invasive esophagectomy and chest wall tumors resection, periareolar biportal sympathetic chain clipping for patients with severe hyperhidrosis, submammary chest wall tumor resection and reconstruction and a VATS training program for fellows and residents.

Lectures by this speaker
Saturday, 2022-11-26
Surgical Advances in NSCLC Management

  14:00 - 14:20

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

  14:00 - 14:20

Controversies in Stage III NSCLC Management

Prof. Abdul Rahman Jazieh | USA

Abdul
Prof. Abdul Rahman Jazieh
Director of Innovations and Research and Director of International Program | USA

"Director of Innovations and Research and Director of International Program at Cincinnati Cancer Advisors, Cincinnati, OH, USA. Editor in Chief, Global Journal on Quality and Safety in Healthcare. Former Chairman and Professor, Department of Oncology and a Professor at King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. Former Professor and Chief of Hematology Oncology Division at University of Cincinnati. Founded the MENA-NCCN Collaborating Center (KSA) and the Association of VA Hematology Oncology (www.avaho.org) (USA). Specialized in hematology, and oncology with master’s Degree in public health in health education and communication. He published more than 100 articles, books, and book chapters. Dr. Jazieh won multiple honors including Proclamation to the City of Cincinnati, naming a day in the City as Dr. Abdul Rahman Jazieh Day in 2006 and Special Recognition from NCCN as Global Partner in Cancer Care 2018. "

Sessions by this speaker
Saturday, 2022-11-26
Session 7: Lung Cancer Session

  15:40 - 17:30

Lectures by this speaker
Saturday, 2022-11-26
Controversies in Stage III NSCLC Management

  14:20 - 14:40

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Saturday, 2022-11-26
Voting + Panel discussion

  17:00 - 17:10

Sunday, 2022-11-27
Case Presentation Lung Cancer

  14:00 - 14:45

  14:20 - 14:40

Recent Advances in Systemic Therapy in Resected Lung Cancer - Supported by Roche

Dr. Tim Benepal | United Kingdom

Tim
Dr. Tim Benepal
Consultant Medical Oncologist | United Kingdom

Dr. Tim Benepal is a BSc, MB BS, FRCP, PhD, Consultant Medical Oncologist and Honorary Senior Lecturer at St Georges University Hospitals NHS Trust, London, UK

Lectures by this speaker
Saturday, 2022-11-26
Recent Advances in Systemic Therapy in Resected Lung Cancer - Supported by Roche

  14:40 - 15:00

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Dr. Emad Dawoud | United Arab Emirates

Emad
Dr. Emad Dawoud
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Emad Dawoud is a Consultant Medical Oncologist in Oncology department at Tawam hospital UAE, and Assistant professor of clinical oncology in Al Azhar University Cairo, Egypt. Dr. Dawoud has been principal investigator and co- investigator for more than 50 clinical trials and abstract published per reviewed journals and he is a member of various associations such as ASCO, ESMO, ESTRO.

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Friday, 2022-11-25
Session 3: Gynaecological cancers

  11:20 - 14:00

Friday, 2022-11-25
Session 5: Gynaecological Cancers

  14:00 - 15:40

Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions

  14:00 - 16:50

Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Lectures by this speaker
Friday, 2022-11-25
Management of endometrial cancer in the molecular era

  15:40 - 16:00

Friday, 2022-11-25
Panel Discussion- Q&A

  15:00 - 15:20

Friday, 2022-11-25
Endometrial Cancer - Case Based Discussion

  12:00 - 12:30

Friday, 2022-11-25
Panel Discussion

  12:30 - 12:40

Friday, 2022-11-25
Panel Discussion- Q&A

  16:20 - 16:30

Saturday, 2022-11-26
Recent Advances in Systemic Therapy in Resected Lung Cancer - Supported by Roche

  14:40 - 15:00

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Sunday, 2022-11-27
Panel Discussion and Q & A

  12:40 - 13:00

Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen

  10:20 - 10:40

Sunday, 2022-11-27
Case Presentation Lung Cancer

  14:00 - 14:45

Sunday, 2022-11-27
Optimizing the 1st line treatment in mCRC - Supported by Merck

  12:00 - 12:20

Sunday, 2022-11-27
Panel Discussion and Q & A

  10:40 - 10:50

Saturday, 2022-11-26
Early Breast Cancer and the Use of Abemacilcib to Prevent Recurrence in Patients with HR+, HER2- with High Risk of Recurrence - Supported by Lilly

  09:50 - 10:10

  14:40 - 15:00

Panel Discussion and Q&A’s

Dr. Maroun Khoury | United Arab Emirates

Maroun
Dr. Maroun Khoury
Consultant Oncologist/ Hematologist | United Arab Emirates

Assistant Professor Doctor Maroun El Khoury Consultant Oncologist/ Hematologist at American Hospital in Dubai 9/2010-Present. Mayo Clinic Network (Jci Accredited), Director Of Cancer Care Center, President of Medical Staff: 2018-2020. Chairperson Scientific Committee, Emirates Oncology Society: 2018-2020 .7/2006-8/2010: Private Practice In The Us/Iowa: Medical Director Of Oncology And Hematology Services And Chief Of Medicine At Great River Health System .7/2006-2010: Hospice Medical Co-Director .Epec (Education In Palliative And End-Of-Life Care) Trainer.

Sessions by this speaker
Saturday, 2022-11-26
Session 5: Lung Cancer Session

  14:00 - 15:40

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Dr. Aref Chehal | United Arab Emirates

Aref
Dr. Aref Chehal
Adjunct Clinical Associate Professor of Medicine | United Arab Emirates

Dr. Chehal is an Adjunct Clinical Associate Professor of Medicine, Gulf Medical University (GMU), Ajman, UAE Dr. Chehal is an Adjunct Clinical Associate Professor of Medicine, Khalifa University (KU), Abu Dhabi, UAE Dr. Chehal graduated from the college of Medicine at Baghdad University/Iraq (MBChB) in 1996. He did his Internal Medicine residency at Makassed General Hospital (Affiliated with American University of Beirut), Lebanon, between 1997 and 2000. He did his Hematology/Oncology fellowship at the American University of Beirut (AUBMC), Lebanon, between 2000 and 2003 (Lebanese Board). He obtained Fellowship of the American College of Physician (FACP) in 2013. He obtained the European Certification of Medical Oncology (ECMO) in 2009 and Re-certification in 2014 and 2021. Dr. Chehal is a member of many national and international societies including ASCO, ESMO, EHA,….. He had an important role in Tumor registry in Lebanon in 2002. Dr. Chehal acted as chairperson, moderator, advisor, and member of scientific committee in many local and international congresses. Dr. Chehal has 27 published articles in peer reviewed international journals; he is the first author on 9 of them, in addition to 31 abstracts. He joined Mafraq hospital From May 2006 until December 2019. He served as head of Hematology Oncology division at Mafraq Hospital from December 2018 till December 2019 His main interests are Lung cancer, Breast Cancer, GI malignancies and Lymphoma.

Sessions by this speaker
Saturday, 2022-11-26
Session 5: Lung Cancer Session

  14:00 - 15:40

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Dr. Norberto Santana | United Arab Emirates

Norberto
Dr. Norberto Santana
Chair of Thoracic Surgery | United Arab Emirates

Dr. Norberto is an experienced surgeon with a strong background in minimally invasive surgery, lung transplantation, hospital management, team leader, education, and translational research. He has recently joined SSMC-Mayo Clinic in Abu Dhabi as Chair of Thoracic Surgery. Previously, he was the Head of Thoracic Surgery and Lung Transplantation at one of the most prestigious hospitals in the Middle East, King Faisal Specialist Hospital & Research Center, ranked 76 worldwide. Here, he has set for the first time in the Kingdom of Saudi Arabia and the Middle East, the uniportal video-assisted thoracic surgery (VATS) program for lung resections, mediastinum, foregut, and pleural diseases, the uniportal VATS lung anatomical segmentectomy program in patients with lung cancer or centrally located lung metastasis to prevent the lobectomy, uniportal VATS decortication program to avoid the thoracotomy in patients with empyema, and the robotic thoracic surgery (RATS) program together with other novel programs such as: VATS cytoreductive surgery plus unidirectional hyperthermic intrathoracic chemotherapy (HITHOC) for patients with malignant pleural diseases (mesothelioma, thymoma, etc.), the introduction of ECMO and CBP for major airway and lung tumor resections, endoscopic closure of bronchopleural fistula, 3D reconstruction for personalized surgical treatment through the planning of lung sparing surgery, minimally invasive esophagectomy and chest wall tumors resection, periareolar biportal sympathetic chain clipping for patients with severe hyperhidrosis, submammary chest wall tumor resection and reconstruction and a VATS training program for fellows and residents.

Lectures by this speaker
Saturday, 2022-11-26
Surgical Advances in NSCLC Management

  14:00 - 14:20

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Prof. Abdul Rahman Jazieh | USA

Abdul
Prof. Abdul Rahman Jazieh
Director of Innovations and Research and Director of International Program | USA

"Director of Innovations and Research and Director of International Program at Cincinnati Cancer Advisors, Cincinnati, OH, USA. Editor in Chief, Global Journal on Quality and Safety in Healthcare. Former Chairman and Professor, Department of Oncology and a Professor at King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. Former Professor and Chief of Hematology Oncology Division at University of Cincinnati. Founded the MENA-NCCN Collaborating Center (KSA) and the Association of VA Hematology Oncology (www.avaho.org) (USA). Specialized in hematology, and oncology with master’s Degree in public health in health education and communication. He published more than 100 articles, books, and book chapters. Dr. Jazieh won multiple honors including Proclamation to the City of Cincinnati, naming a day in the City as Dr. Abdul Rahman Jazieh Day in 2006 and Special Recognition from NCCN as Global Partner in Cancer Care 2018. "

Sessions by this speaker
Saturday, 2022-11-26
Session 7: Lung Cancer Session

  15:40 - 17:30

Lectures by this speaker
Saturday, 2022-11-26
Controversies in Stage III NSCLC Management

  14:20 - 14:40

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Saturday, 2022-11-26
Voting + Panel discussion

  17:00 - 17:10

Sunday, 2022-11-27
Case Presentation Lung Cancer

  14:00 - 14:45

Dr. Tim Benepal | United Kingdom

Tim
Dr. Tim Benepal
Consultant Medical Oncologist | United Kingdom

Dr. Tim Benepal is a BSc, MB BS, FRCP, PhD, Consultant Medical Oncologist and Honorary Senior Lecturer at St Georges University Hospitals NHS Trust, London, UK

Lectures by this speaker
Saturday, 2022-11-26
Recent Advances in Systemic Therapy in Resected Lung Cancer - Supported by Roche

  14:40 - 15:00

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Dr. Diaeddine Trad | United Arab Emirates

Diaeddine
Dr. Diaeddine Trad
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Diaeddine Trad is a Consultant of Medical Oncology, at Tawam Hospital, in Al Ain, UAE. He is a member of the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). He is an investigator in several ongoing clinical trials. Dr. Trad is certified as a specialist in internal medicine, hematology and oncology by the Lebanese Ministry of Health. His research interests include; non-small cell lung adenocarcinoma and locally advanced breast cancer. Dr. Trad was a speaker in many international conferences and forums.

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 5: Lung Cancer Session

  14:00 - 15:40

Sunday, 2022-11-27
Session 3: Gastrointestinal Session

  11:00 - 14:00

Saturday, 2022-11-26
Session 7: Lung Cancer Session

  15:40 - 17:30

Lectures by this speaker
Saturday, 2022-11-26
Real world effectiveness data for MBC patients – Supported by Pfizer

  12:20 - 12:40

Saturday, 2022-11-26
Panel Discussion and Q&A

  13:00 - 13:10

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Saturday, 2022-11-26
Closing Remarks

  17:10 - 17:20

Sunday, 2022-11-27
Panel Discussion and Q & A

  12:40 - 13:00

Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions

  16:00 - 16:40

Sunday, 2022-11-27
Meeting Close

  16:35 - 16:40

Sunday, 2022-11-27
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly

  12:20 - 12:40

Dr. Emad Dawoud | United Arab Emirates

Emad
Dr. Emad Dawoud
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Emad Dawoud is a Consultant Medical Oncologist in Oncology department at Tawam hospital UAE, and Assistant professor of clinical oncology in Al Azhar University Cairo, Egypt. Dr. Dawoud has been principal investigator and co- investigator for more than 50 clinical trials and abstract published per reviewed journals and he is a member of various associations such as ASCO, ESMO, ESTRO.

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Friday, 2022-11-25
Session 3: Gynaecological cancers

  11:20 - 14:00

Friday, 2022-11-25
Session 5: Gynaecological Cancers

  14:00 - 15:40

Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions

  14:00 - 16:50

Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Lectures by this speaker
Friday, 2022-11-25
Management of endometrial cancer in the molecular era

  15:40 - 16:00

Friday, 2022-11-25
Panel Discussion- Q&A

  15:00 - 15:20

Friday, 2022-11-25
Endometrial Cancer - Case Based Discussion

  12:00 - 12:30

Friday, 2022-11-25
Panel Discussion

  12:30 - 12:40

Friday, 2022-11-25
Panel Discussion- Q&A

  16:20 - 16:30

Saturday, 2022-11-26
Recent Advances in Systemic Therapy in Resected Lung Cancer - Supported by Roche

  14:40 - 15:00

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Sunday, 2022-11-27
Panel Discussion and Q & A

  12:40 - 13:00

Sunday, 2022-11-27
Apalutamide from Clinical Trials to Clinical Practice - Supported by Janssen

  10:20 - 10:40

Sunday, 2022-11-27
Case Presentation Lung Cancer

  14:00 - 14:45

Sunday, 2022-11-27
Optimizing the 1st line treatment in mCRC - Supported by Merck

  12:00 - 12:20

Sunday, 2022-11-27
Panel Discussion and Q & A

  10:40 - 10:50

Saturday, 2022-11-26
Early Breast Cancer and the Use of Abemacilcib to Prevent Recurrence in Patients with HR+, HER2- with High Risk of Recurrence - Supported by Lilly

  09:50 - 10:10

  15:00 - 15:10

Beyond Covid 19 Vaccination : Evusheld (Tixagevimab and Cilgevimab ) for the Prevention and Treatment of Covid 19 among the High Risk Patients - Supported by AstraZeneca

Dr. Jehad Abdullah | United Arab Emirates

Jehad
Dr. Jehad Abdullah
Consultant infectious disease | United Arab Emirates

Dr. Jehad Abdalla, M.D. is an American board-certified in both Internal Medicine and Infectious Diseases, currently works as an Infectious Diseases consultant at Al Rahba hospital in Abu Dhabi, head of the infection control and prevention committee and chairperson of antibiotic stewardship program and at Al Rahba hospital. Dr. Abdalla has a special interest in Tuberculosis as well as HIV management.

Lectures by this speaker
Saturday, 2022-11-26
Beyond Covid 19 Vaccination : Evusheld (Tixagevimab and Cilgevimab ) for the Prevention and Treatment of Covid 19 among the High Risk Patients - Supported by AstraZeneca

  15:10 - 15:30

Dr. Nouri Bennini | United Arab Emirates

Nouri
Dr. Nouri Bennini
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr.Nouri Bennini is a Consultant Physician, Oncology Clinic at Tawam Hospital.

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 1: Early Breast Cancer Session

  08:30 - 11:00

Sunday, 2022-11-27
Session 5: Gastrointestinal Session

  14:00 - 16:40

Sunday, 2022-11-27
Educational Sessions: Multi-Disciplinary Case Based Discussions

  14:00 - 16:50

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:10 - 10:30

Saturday, 2022-11-26
Beyond Covid 19 Vaccination : Evusheld (Tixagevimab and Cilgevimab ) for the Prevention and Treatment of Covid 19 among the High Risk Patients - Supported by AstraZeneca

  15:10 - 15:30

Sunday, 2022-11-27
Panel Discussion and Q&A’s

  15:20 - 15:30

Sunday, 2022-11-27
Dual Immunotherapy Approach in 1L RCC Treatment - Supported by BMS

  11:20 - 11:50

Sunday, 2022-11-27
Case Presentation Breast Cancer

  14:45 - 15:30

Sunday, 2022-11-27
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly

  12:20 - 12:40

  15:10 - 15:30

Session 7: Lung Cancer Session
Chairperson:

Prof. Abdul Rahman Jazieh | USA

Abdul
Prof. Abdul Rahman Jazieh
Director of Innovations and Research and Director of International Program | USA

"Director of Innovations and Research and Director of International Program at Cincinnati Cancer Advisors, Cincinnati, OH, USA. Editor in Chief, Global Journal on Quality and Safety in Healthcare. Former Chairman and Professor, Department of Oncology and a Professor at King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. Former Professor and Chief of Hematology Oncology Division at University of Cincinnati. Founded the MENA-NCCN Collaborating Center (KSA) and the Association of VA Hematology Oncology (www.avaho.org) (USA). Specialized in hematology, and oncology with master’s Degree in public health in health education and communication. He published more than 100 articles, books, and book chapters. Dr. Jazieh won multiple honors including Proclamation to the City of Cincinnati, naming a day in the City as Dr. Abdul Rahman Jazieh Day in 2006 and Special Recognition from NCCN as Global Partner in Cancer Care 2018. "

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -


Chairperson:

Dr. Omran El Koha | United Arab Emirates

Omran El
Dr. Omran El Koha
Consultant Radiation /Clinical Oncologist | United Arab Emirates

Dr. Omran is an experienced clinical oncologist with a demonstrated history of working in the medical and radiation oncology p . Skilled in Clinical Research, Medical Education, Strategic Planning. Strong education professional with a Master's Degree focused in Health research ethics

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -


Chairperson:

Dr. Diaeddine Trad | United Arab Emirates

Diaeddine
Dr. Diaeddine Trad
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Diaeddine Trad is a Consultant of Medical Oncology, at Tawam Hospital, in Al Ain, UAE. He is a member of the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). He is an investigator in several ongoing clinical trials. Dr. Trad is certified as a specialist in internal medicine, hematology and oncology by the Lebanese Ministry of Health. His research interests include; non-small cell lung adenocarcinoma and locally advanced breast cancer. Dr. Trad was a speaker in many international conferences and forums.

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -

Thursday,

  -


  15:40 - 17:30

Systemic therapy advances in extensive stage Small cell lung cancer

Dr. Fathi Azribi | United Arab Emirates

Fathi
Dr. Fathi Azribi
Consultant Medical Oncologist | United Arab Emirates

Dr Fathi Azribi is a Consultant Medical Oncologist. He graduated from Tripoli University, Libya, then completed specialty training in Oncology in the UK and obtained a Certificate of Completion of Training in Medical Oncology. His main interest is in thoracic, breast, gynaecological and gastrointestinal malignancies, with expertise in treatment with chemotherapy, immunotherapy, hormonal, and targeted therapy. He published several papers and abstracts in peer reviewed journals. He also founded the first Medical Oncology Fellowship program in the UAE.

Sessions by this speaker
Friday, 2022-11-25
Session 5: Gynaecological Cancers

  14:00 - 15:40

Friday, 2022-11-25
Session 7: Gynaecological cancers

  15:40 - 16:50

Lectures by this speaker
Friday, 2022-11-25
Panel Discussion- Q&A

  15:00 - 15:20

Friday, 2022-11-25
Advances in immunotherapy for Cervical Cancer

  16:00 - 16:20

Friday, 2022-11-25
Panel Discussion- Q&A

  16:20 - 16:30

Saturday, 2022-11-26
Systemic therapy advances in extensive stage Small cell lung cancer

  15:40 - 16:00

Saturday, 2022-11-26
Voting + Panel discussion

  17:00 - 17:10

  15:40 - 16:00

Molecular targeted therapies for NSCLC- recent advances

Dr. Johan F Vansteenkiste | Belgium

Johan
Dr. Johan F Vansteenkiste
Professor of Internal Medicine | Belgium

"Johan F. Vansteenkiste is a Professor of Internal Medicine in the Faculty of Medicine at the Catholic University of Leuven, Belgium, and Head of Clinic in the Respiratory Oncology Unit and its Clinical Trial Unit at the Leuven University Hospital, Belgium. Professor Vansteenkiste studied Medicine at the Catholic University of Leuven before becoming a Board Certified Pulmonologist-Oncologist. He had additional training in Respiratory Oncology at the European School of Oncology in Milan, Italy, and in Respiratory Endoscopy at the Laser entre in Marseille, France, before gaining his Ph.D. at the Catholic University of Leuven in 1996. Professor Vansteenkiste is an active member of different national and international societies such as IASLC, ASCO, ESMO, ERS, and others. He is a member of the Board of Directors of IASLC from 2009-to 2013 and a member of the ESMO Lung Educational Group and Guidelines Group. He was Secretary of the Thoracic Oncology Assembly of the ERS and a member of the ERS School Board from 2009-to 2012. He is the principal investigator or co-investigator in several clinical trials in the area of lung cancer. He is an Associate Editor at the Journal of Thoracic Oncology, a member of the editorial board of the Journal of Clinical Oncology and several other journals, and author or co-author of more than 200 peer-reviewed papers and book chapters on Respiratory Oncology."

Lectures by this speaker
Saturday, 2022-11-26
Molecular targeted therapies for NSCLC- recent advances

  16:00 - 16:20

Saturday, 2022-11-26
Voting + Panel discussion

  17:00 - 17:10

  16:00 - 16:20

Single agent checkpoint inhibitor + chemotherapy is the preferred option?

Dr. Faraz Khan | United Arab Emirates

Faraz
Dr. Faraz Khan
Head Of Hematology Program | United Arab Emirates

Asst Prof Dr. Faraz Khan is a Consultant Hematologist and Medical Oncologist with over 15 years experience in treating cancer and various blood diseases. He completed his Internal Medicine, Hematology and Medical oncology training from the University of Connecticut, CT, USA and is triple board certified in Internal medicine, Hematology and Medical Oncology. He worked as a consultant Hematologist/Medical Oncologist at PEI Cancer Treatment Center, PE, Canada and directed the provincial hemophilia and bleeding disorder clinic.

Sessions by this speaker
Saturday, 2022-11-26
Session 2: Haematological Malignancies

  08:30 - 11:00

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Saturday, 2022-11-26
Single agent checkpoint inhibitor + chemotherapy is the preferred option?

  16:20 - 16:40

Saturday, 2022-11-26
Voting + Panel discussion

  17:00 - 17:10

  16:20 - 16:40

Dual checkpoint blockade + chemotherapy is the preferred option?

Dr. Ignacio Gil-Bazo | Spain

Ignacio
Dr. Ignacio Gil-Bazo
Head of the Department of Oncology | Spain

"Prof. Gil-Bazo is the Head of the Department of Oncology and Scientific Director of the Valencian Institute of Oncology (IVO) in the city of Valencia, Spain. He has previously served as Chairman of the Department of Oncology at the University of Navarra, in Pamplona, Spain. In addition, he is Associate Professor of Medicine at the Department of Oncology at the University of Navarra School of Medicine and Director of the New Therapeutic Targets Laboratory of the Program in Solid Tumors at the Center for Applied Medical Research (CIMA). Prof. Gil-Bazo is a Medical Oncologist with expertise in Thoracic Oncology, Translational Research in Oncology and Clinical Investigation. The Valencian Institute of Oncology (IVO), an OECI accredited Cancer Center, is a nationally and internationally renowned institution, the largest and most prestigious private cancer center in Spain."

Lectures by this speaker
Saturday, 2022-11-26
Dual checkpoint blockade + chemotherapy is the preferred option?

  16:40 - 17:00

Saturday, 2022-11-26
Voting + Panel discussion

  17:00 - 17:10

Sunday, 2022-11-27
Case Presentation Lung Cancer

  14:00 - 14:45

  16:40 - 17:00

Voting + Panel discussion

Prof. Abdul Rahman Jazieh | USA

Abdul
Prof. Abdul Rahman Jazieh
Director of Innovations and Research and Director of International Program | USA

"Director of Innovations and Research and Director of International Program at Cincinnati Cancer Advisors, Cincinnati, OH, USA. Editor in Chief, Global Journal on Quality and Safety in Healthcare. Former Chairman and Professor, Department of Oncology and a Professor at King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. Former Professor and Chief of Hematology Oncology Division at University of Cincinnati. Founded the MENA-NCCN Collaborating Center (KSA) and the Association of VA Hematology Oncology (www.avaho.org) (USA). Specialized in hematology, and oncology with master’s Degree in public health in health education and communication. He published more than 100 articles, books, and book chapters. Dr. Jazieh won multiple honors including Proclamation to the City of Cincinnati, naming a day in the City as Dr. Abdul Rahman Jazieh Day in 2006 and Special Recognition from NCCN as Global Partner in Cancer Care 2018. "

Sessions by this speaker
Saturday, 2022-11-26
Session 7: Lung Cancer Session

  15:40 - 17:30

Lectures by this speaker
Saturday, 2022-11-26
Controversies in Stage III NSCLC Management

  14:20 - 14:40

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Saturday, 2022-11-26
Voting + Panel discussion

  17:00 - 17:10

Sunday, 2022-11-27
Case Presentation Lung Cancer

  14:00 - 14:45

Dr. Ignacio Gil-Bazo | Spain

Ignacio
Dr. Ignacio Gil-Bazo
Head of the Department of Oncology | Spain

"Prof. Gil-Bazo is the Head of the Department of Oncology and Scientific Director of the Valencian Institute of Oncology (IVO) in the city of Valencia, Spain. He has previously served as Chairman of the Department of Oncology at the University of Navarra, in Pamplona, Spain. In addition, he is Associate Professor of Medicine at the Department of Oncology at the University of Navarra School of Medicine and Director of the New Therapeutic Targets Laboratory of the Program in Solid Tumors at the Center for Applied Medical Research (CIMA). Prof. Gil-Bazo is a Medical Oncologist with expertise in Thoracic Oncology, Translational Research in Oncology and Clinical Investigation. The Valencian Institute of Oncology (IVO), an OECI accredited Cancer Center, is a nationally and internationally renowned institution, the largest and most prestigious private cancer center in Spain."

Lectures by this speaker
Saturday, 2022-11-26
Dual checkpoint blockade + chemotherapy is the preferred option?

  16:40 - 17:00

Saturday, 2022-11-26
Voting + Panel discussion

  17:00 - 17:10

Sunday, 2022-11-27
Case Presentation Lung Cancer

  14:00 - 14:45

Dr. Fathi Azribi | United Arab Emirates

Fathi
Dr. Fathi Azribi
Consultant Medical Oncologist | United Arab Emirates

Dr Fathi Azribi is a Consultant Medical Oncologist. He graduated from Tripoli University, Libya, then completed specialty training in Oncology in the UK and obtained a Certificate of Completion of Training in Medical Oncology. His main interest is in thoracic, breast, gynaecological and gastrointestinal malignancies, with expertise in treatment with chemotherapy, immunotherapy, hormonal, and targeted therapy. He published several papers and abstracts in peer reviewed journals. He also founded the first Medical Oncology Fellowship program in the UAE.

Sessions by this speaker
Friday, 2022-11-25
Session 5: Gynaecological Cancers

  14:00 - 15:40

Friday, 2022-11-25
Session 7: Gynaecological cancers

  15:40 - 16:50

Lectures by this speaker
Friday, 2022-11-25
Panel Discussion- Q&A

  15:00 - 15:20

Friday, 2022-11-25
Advances in immunotherapy for Cervical Cancer

  16:00 - 16:20

Friday, 2022-11-25
Panel Discussion- Q&A

  16:20 - 16:30

Saturday, 2022-11-26
Systemic therapy advances in extensive stage Small cell lung cancer

  15:40 - 16:00

Saturday, 2022-11-26
Voting + Panel discussion

  17:00 - 17:10

Dr. Faraz Khan | United Arab Emirates

Faraz
Dr. Faraz Khan
Head Of Hematology Program | United Arab Emirates

Asst Prof Dr. Faraz Khan is a Consultant Hematologist and Medical Oncologist with over 15 years experience in treating cancer and various blood diseases. He completed his Internal Medicine, Hematology and Medical oncology training from the University of Connecticut, CT, USA and is triple board certified in Internal medicine, Hematology and Medical Oncology. He worked as a consultant Hematologist/Medical Oncologist at PEI Cancer Treatment Center, PE, Canada and directed the provincial hemophilia and bleeding disorder clinic.

Sessions by this speaker
Saturday, 2022-11-26
Session 2: Haematological Malignancies

  08:30 - 11:00

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Saturday, 2022-11-26
Single agent checkpoint inhibitor + chemotherapy is the preferred option?

  16:20 - 16:40

Saturday, 2022-11-26
Voting + Panel discussion

  17:00 - 17:10

Dr. Johan F Vansteenkiste | Belgium

Johan
Dr. Johan F Vansteenkiste
Professor of Internal Medicine | Belgium

"Johan F. Vansteenkiste is a Professor of Internal Medicine in the Faculty of Medicine at the Catholic University of Leuven, Belgium, and Head of Clinic in the Respiratory Oncology Unit and its Clinical Trial Unit at the Leuven University Hospital, Belgium. Professor Vansteenkiste studied Medicine at the Catholic University of Leuven before becoming a Board Certified Pulmonologist-Oncologist. He had additional training in Respiratory Oncology at the European School of Oncology in Milan, Italy, and in Respiratory Endoscopy at the Laser entre in Marseille, France, before gaining his Ph.D. at the Catholic University of Leuven in 1996. Professor Vansteenkiste is an active member of different national and international societies such as IASLC, ASCO, ESMO, ERS, and others. He is a member of the Board of Directors of IASLC from 2009-to 2013 and a member of the ESMO Lung Educational Group and Guidelines Group. He was Secretary of the Thoracic Oncology Assembly of the ERS and a member of the ERS School Board from 2009-to 2012. He is the principal investigator or co-investigator in several clinical trials in the area of lung cancer. He is an Associate Editor at the Journal of Thoracic Oncology, a member of the editorial board of the Journal of Clinical Oncology and several other journals, and author or co-author of more than 200 peer-reviewed papers and book chapters on Respiratory Oncology."

Lectures by this speaker
Saturday, 2022-11-26
Molecular targeted therapies for NSCLC- recent advances

  16:00 - 16:20

Saturday, 2022-11-26
Voting + Panel discussion

  17:00 - 17:10

Dr. Omran El Koha | United Arab Emirates

Omran El
Dr. Omran El Koha
Consultant Radiation /Clinical Oncologist | United Arab Emirates

Dr. Omran is an experienced clinical oncologist with a demonstrated history of working in the medical and radiation oncology p . Skilled in Clinical Research, Medical Education, Strategic Planning. Strong education professional with a Master's Degree focused in Health research ethics

Sessions by this speaker
Sunday, 2022-11-27
Session 1: Paediatric Oncology

  08:30 - 11:00

Saturday, 2022-11-26
Session 7: Lung Cancer Session

  15:40 - 17:30

Lectures by this speaker
Saturday, 2022-11-26
Voting + Panel discussion

  17:00 - 17:10

Sunday, 2022-11-27
Case Presentation Lung Cancer

  14:00 - 14:45

Sunday, 2022-11-27
Panel Discussion and Q&A’s

  10:10 - 10:30

  17:00 - 17:10

Closing Remarks

Dr. Diaeddine Trad | United Arab Emirates

Diaeddine
Dr. Diaeddine Trad
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr. Diaeddine Trad is a Consultant of Medical Oncology, at Tawam Hospital, in Al Ain, UAE. He is a member of the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). He is an investigator in several ongoing clinical trials. Dr. Trad is certified as a specialist in internal medicine, hematology and oncology by the Lebanese Ministry of Health. His research interests include; non-small cell lung adenocarcinoma and locally advanced breast cancer. Dr. Trad was a speaker in many international conferences and forums.

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 5: Lung Cancer Session

  14:00 - 15:40

Sunday, 2022-11-27
Session 3: Gastrointestinal Session

  11:00 - 14:00

Saturday, 2022-11-26
Session 7: Lung Cancer Session

  15:40 - 17:30

Lectures by this speaker
Saturday, 2022-11-26
Real world effectiveness data for MBC patients – Supported by Pfizer

  12:20 - 12:40

Saturday, 2022-11-26
Panel Discussion and Q&A

  13:00 - 13:10

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  15:00 - 15:10

Saturday, 2022-11-26
Closing Remarks

  17:10 - 17:20

Sunday, 2022-11-27
Panel Discussion and Q & A

  12:40 - 13:00

Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions

  16:00 - 16:40

Sunday, 2022-11-27
Meeting Close

  16:35 - 16:40

Sunday, 2022-11-27
Gastric Cancer-ESMO Guidelines Update - Supported by Lilly

  12:20 - 12:40

  17:10 - 17:20


Session 2: Haematological Malignancies
Chairperson:

Dr. Faraz Khan | United Arab Emirates

Faraz
Dr. Faraz Khan
Head Of Hematology Program | United Arab Emirates

Asst Prof Dr. Faraz Khan is a Consultant Hematologist and Medical Oncologist with over 15 years experience in treating cancer and various blood diseases. He completed his Internal Medicine, Hematology and Medical oncology training from the University of Connecticut, CT, USA and is triple board certified in Internal medicine, Hematology and Medical Oncology. He worked as a consultant Hematologist/Medical Oncologist at PEI Cancer Treatment Center, PE, Canada and directed the provincial hemophilia and bleeding disorder clinic.

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -

Thursday,

  -


Chairperson:

Dr. Shahrukh Hashmi | United Arab Emirates

Shahrukh
Dr. Shahrukh Hashmi
Chairman | United Arab Emirates

"Dr. Shahrukh Hashmi is the acting Dean of Research at SSMC, Abu Dhabi, UAE. He graduated from Baqai Medical University, Pakistan, as the top graduate receiving Gold Medal from the President of Pakistan. He received Master’s Degree (MPH) from Yale University, Connecticut, USA. He is a Diplomat of the American Board of Preventive Medicine/Public Health, Internal Medicine, and Hematology. He has been at Mayo Clinic, Minnesota, USA for >10 years. He started Mayo Clinic’s first BMT survivorship program. He has served as PI or Co-PI on many industry-sponsored and NIH sponsored trials. His research interests include premature aging, artificial intelligence, and GVHD. He is also involved in Stem Cell Therapeutics particularly in regenerative hematology. He has authored >220 articles in peer-reviewed journals, including in JAMA, Lancet, and in NEJM. He chairs many national or international professional committees/groups including being the chair of the Worldwide Network for Blood and Marrow Transplant’s Nuclear Accident committee (Geneva, Switzerland), founding chair of American Society for Blood and Marrow Transplant Society’s Survivorship SIG (Chicago, Illinois), and co-chair of the Center for International Blood & Marrow Transplant Registry’s (CIBMTR) Health Services Committee (Milwaukee, Wisconsin). He is currently the chairperson of the Dept. of Hematology/Oncology at the SSMC, Abu Dhabi, UAE, and the chairperson of SEHA Oncology Council. He is also faculty at Khalifa University, UAE, and adjunct faculty at Mohamad Bin Zayed University of Artificial Intelligence, UAE."

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -


Chairperson:

Dr. Amar Lal | United Arab Emirates

Amar
Dr. Amar Lal
Hematologist and Oncologist | United Arab Emirates

"Dr. Amar Lal graduated from Dow University in 1993. He underwent medicine residency and followed by oncology fellowship. He qualified triple diploma in medicine, family medicine and oncology from CPSP Pakistan. Then he got triple diplomas from Royal Colleges of Physicians Ireland and Glasgow in medicine and speciality certificates oncology royal college London. He also qualified ESMO Examination Board in oncology. He has been local and international speaker in hematology and oncology and has more than 40 publications. He joined Tawam hospital in 2007 and he continued to be an active part of CME/ Scientific Program Coordinator, Member of Pharmacy & Therapeutics Committee (PTC), Patient safety physician manager, Member of Medication Utilization Committee (MSSC). "

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -


  08:30 - 11:00

Welcome Note

Dr. Arif Raza Alam | United Arab Emirates

Arif
Dr. Arif Raza Alam
Chief of Hematology | United Arab Emirates

Chief of Hematology – Tawam Hospital

Sessions by this speaker
Friday, 2022-11-25
Scientific Committee

  00:00 - 23:55

Lectures by this speaker
Saturday, 2022-11-26
Welcome Note

  08:30 - 08:32

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Saturday, 2022-11-26
A new Era in Front-Line CLL Management - Supported by Janssen

  09:50 - 10:10

  08:30 - 08:32

Treating CLL in 2022: A Critical Evaluation of BTKis and Other Novel Agents

Prof. Mahmoud Marashi | United Arab Emirates

Mahmoud
Prof. Mahmoud Marashi
Consultant Haematologist | United Arab Emirates

"Prof. Mahmoud Marashi joined Mediclinic City Hospital as Consultant Haematologist with over 30 years experience in haematology. He established the clinical haematology service in Dubai Health Authority which is involved in the management of both benign disorders (anaemias, bleeding disorders, thrombosis/thrombophilia) and malignant disorders (acute and chronic leukaemias, myeloma, myeloproliferative disorders, myelodysplastic syndrome). He runs both an undergraduate and postgraduate training in Haematology. Prof. Marashi did his undergraduate training in Andhra University, India. His haematology training was done in the UL at Heartlands Hospital, Birmingham, (formerly East Birmingham Hospital), The West Midlands Blood Transfusion Service, Edgbaston, Birmingham, The John Radcliffe Hospital and Chuchill Hospital in Oxford, UK. Prof. Marashi has been involved in medical education for over 20 years. He is a Professor of Medicine and Haematology and is the Head of the Academic Department of Medicine, Dubai Medical College / Dubai Health Authority. He is also an external examiner for the Royal College of Physicians of UK. *Independent Doctors (ID): Defined as individuals not employed by Mediclinic Middle East who are granted the privilege to treat patient at MCME facilities, in either inpatient or outpatient settings, as applicable."

Lectures by this speaker
Saturday, 2022-11-26
Treating CLL in 2022: A Critical Evaluation of BTKis and Other Novel Agents

  08:30 - 08:50

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Saturday, 2022-11-26
A new Era in Front-Line CLL Management - Supported by Janssen

  09:50 - 10:10

  08:30 - 08:50

CNS Lymphoma debate There is a role of radiotherapy in primary CNS Lymphoma

Dr. Syed Mansoor Hasnain | United Arab Emirates

Syed Mansoor
Dr. Syed Mansoor Hasnain
Consultant Radiation Oncologist | United Arab Emirates

"Dr. Syed Mansoor Hasnain is working in Tawam Hospital, Alain, UAE as Consultant Radiation Oncologist. He joined Tawam Hospital in 2009. He initially trained as surgeon and did fellowship in surgery ,FRCS(Glasg) from Royal College Of Physicians and Surgeons Of Glasgow in 2000. In 2001 he started his career and specialist registrar Training in radiation Oncology under supervision of Faculty of Radiology, The Royal College Of Surgeons In Ireland in Saint Luke’s Hospital. He passed FRCR part 1 from Royal College of Radiologists, London U.K. He did fellowship in radiotherapy ‘FFR RCSI’ from Faculty of Radiology , Royal College Of Surgeons In Ireland in 2007. In 2010 he got CCST 'completion of certified specialist training certificate’ from Faculty of Radiology, The Royal College Of Surgeons In Ireland and entry in to specialist register in Medical Council of Ireland. In Tawam in early 2011, Dr. Mansoor successfully led the commissioning and clinical use of the HiArt TomoTherapy system with IMRT & IGRT, one and only in UAE. . In 2013 Dr. Mansoor chaired RapidArc committee, making sure smooth and swift implementation of RapidArc technology with IMRT & IGRT capability in Tawam. In 2015 Dr. Mansoor was appointed as Adjunct Assistant Professor in College of Medicine and health Sciences in UAE University. . In 2018 as lead radiation oncologist, he successfully led the QUATRO certification of the radiotherapy department by IAEA. He is clinical lead Radiation oncologist for Lymphoma, Sarcoma, Urology & GI tumours. "

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Saturday, 2022-11-26
CNS Lymphoma debate There is a role of radiotherapy in primary CNS Lymphoma

  08:50 - 09:10

Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions

  16:00 - 16:40

Sunday, 2022-11-27
Case Presentation Breast Cancer

  14:45 - 15:30

  08:50 - 09:10

CNS Lymphoma debate: There is no role of radiotherapy in Primary CNS lymphoma

Dr. Hani Osman | United Arab Emirates

Hani
Dr. Hani Osman
Consultant Oncologist | United Arab Emirates

"Dr. Hani Yousif Osman graduated from the Faculty of the Medicine University of Khartoum Sudan. He moved to the United Kingdom where he completed his training in internal medicine and obtained his MRCP (UK) degree, Fellowship from the Royal college of pathologists and CCT. He completed his high specialist training in hematology at the University of Cardiff hospital UK. His research focuses on acute myeloid leukemia novel therapy, He has extensive hematology consultant experience in the UK, Saudia Arabia, and the United Arab Emirates. Dr. Osman was involved and the principle investigator for many clinical trials and he has over 30 publications.

Lectures by this speaker
Saturday, 2022-11-26
CNS Lymphoma debate: There is no role of radiotherapy in Primary CNS lymphoma

  09:10 - 09:30

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Saturday, 2022-11-26
Be Ready for R/R AML – approach for FLT3+ Patients - Supported by Astellas

  10:10 - 10:30

  09:10 - 09:30

Is there a role for intensive chemotherapy for AML in 2022?

Prof. Giovanni Martinelli | Italy

Giovanni
Prof. Giovanni Martinelli
Associate Professor | Italy

Prof. Giovanni Martinelli Scientific Director Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl – IRCCS - Italy. His research and clinical activity involve the area of acute and chronic myeloid leukemia (AML and CML), acute lymphoblastic leukemia (ALL) and myelodisplastic syndromes (MDS). His expertise is in Conduction of several Phase I-II-III clinical trials and biological research projects on AML, ALL, MDS and CML as Principal Investigator, with good knowledge of Good Clinical Practice. He has the skills, expertise and authority to lead a team and he has the capacity of using the resources in a flexible way, to achieve the project objectives.

Lectures by this speaker
Saturday, 2022-11-26
Is there a role for intensive chemotherapy for AML in 2022?

  09:30 - 09:50

Saturday, 2022-11-26
Be Ready for R/R AML – approach for FLT3+ Patients - Supported by Astellas

  10:10 - 10:30

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

  09:30 - 09:50

A new Era in Front-Line CLL Management - Supported by Janssen

Prof. Mahmoud Marashi | United Arab Emirates

Mahmoud
Prof. Mahmoud Marashi
Consultant Haematologist | United Arab Emirates

"Prof. Mahmoud Marashi joined Mediclinic City Hospital as Consultant Haematologist with over 30 years experience in haematology. He established the clinical haematology service in Dubai Health Authority which is involved in the management of both benign disorders (anaemias, bleeding disorders, thrombosis/thrombophilia) and malignant disorders (acute and chronic leukaemias, myeloma, myeloproliferative disorders, myelodysplastic syndrome). He runs both an undergraduate and postgraduate training in Haematology. Prof. Marashi did his undergraduate training in Andhra University, India. His haematology training was done in the UL at Heartlands Hospital, Birmingham, (formerly East Birmingham Hospital), The West Midlands Blood Transfusion Service, Edgbaston, Birmingham, The John Radcliffe Hospital and Chuchill Hospital in Oxford, UK. Prof. Marashi has been involved in medical education for over 20 years. He is a Professor of Medicine and Haematology and is the Head of the Academic Department of Medicine, Dubai Medical College / Dubai Health Authority. He is also an external examiner for the Royal College of Physicians of UK. *Independent Doctors (ID): Defined as individuals not employed by Mediclinic Middle East who are granted the privilege to treat patient at MCME facilities, in either inpatient or outpatient settings, as applicable."

Lectures by this speaker
Saturday, 2022-11-26
Treating CLL in 2022: A Critical Evaluation of BTKis and Other Novel Agents

  08:30 - 08:50

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Saturday, 2022-11-26
A new Era in Front-Line CLL Management - Supported by Janssen

  09:50 - 10:10

Dr. Arif Raza Alam | United Arab Emirates

Arif
Dr. Arif Raza Alam
Chief of Hematology | United Arab Emirates

Chief of Hematology – Tawam Hospital

Sessions by this speaker
Friday, 2022-11-25
Scientific Committee

  00:00 - 23:55

Lectures by this speaker
Saturday, 2022-11-26
Welcome Note

  08:30 - 08:32

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Saturday, 2022-11-26
A new Era in Front-Line CLL Management - Supported by Janssen

  09:50 - 10:10

  09:50 - 10:10

Be Ready for R/R AML – approach for FLT3+ Patients - Supported by Astellas

Prof. Giovanni Martinelli | Italy

Giovanni
Prof. Giovanni Martinelli
Associate Professor | Italy

Prof. Giovanni Martinelli Scientific Director Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl – IRCCS - Italy. His research and clinical activity involve the area of acute and chronic myeloid leukemia (AML and CML), acute lymphoblastic leukemia (ALL) and myelodisplastic syndromes (MDS). His expertise is in Conduction of several Phase I-II-III clinical trials and biological research projects on AML, ALL, MDS and CML as Principal Investigator, with good knowledge of Good Clinical Practice. He has the skills, expertise and authority to lead a team and he has the capacity of using the resources in a flexible way, to achieve the project objectives.

Lectures by this speaker
Saturday, 2022-11-26
Is there a role for intensive chemotherapy for AML in 2022?

  09:30 - 09:50

Saturday, 2022-11-26
Be Ready for R/R AML – approach for FLT3+ Patients - Supported by Astellas

  10:10 - 10:30

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Dr. Hani Osman | United Arab Emirates

Hani
Dr. Hani Osman
Consultant Oncologist | United Arab Emirates

"Dr. Hani Yousif Osman graduated from the Faculty of the Medicine University of Khartoum Sudan. He moved to the United Kingdom where he completed his training in internal medicine and obtained his MRCP (UK) degree, Fellowship from the Royal college of pathologists and CCT. He completed his high specialist training in hematology at the University of Cardiff hospital UK. His research focuses on acute myeloid leukemia novel therapy, He has extensive hematology consultant experience in the UK, Saudia Arabia, and the United Arab Emirates. Dr. Osman was involved and the principle investigator for many clinical trials and he has over 30 publications.

Lectures by this speaker
Saturday, 2022-11-26
CNS Lymphoma debate: There is no role of radiotherapy in Primary CNS lymphoma

  09:10 - 09:30

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Saturday, 2022-11-26
Be Ready for R/R AML – approach for FLT3+ Patients - Supported by Astellas

  10:10 - 10:30

  10:10 - 10:30

Panel Discussion and Q&A’s

Dr. Hani Osman | United Arab Emirates

Hani
Dr. Hani Osman
Consultant Oncologist | United Arab Emirates

"Dr. Hani Yousif Osman graduated from the Faculty of the Medicine University of Khartoum Sudan. He moved to the United Kingdom where he completed his training in internal medicine and obtained his MRCP (UK) degree, Fellowship from the Royal college of pathologists and CCT. He completed his high specialist training in hematology at the University of Cardiff hospital UK. His research focuses on acute myeloid leukemia novel therapy, He has extensive hematology consultant experience in the UK, Saudia Arabia, and the United Arab Emirates. Dr. Osman was involved and the principle investigator for many clinical trials and he has over 30 publications.

Lectures by this speaker
Saturday, 2022-11-26
CNS Lymphoma debate: There is no role of radiotherapy in Primary CNS lymphoma

  09:10 - 09:30

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Saturday, 2022-11-26
Be Ready for R/R AML – approach for FLT3+ Patients - Supported by Astellas

  10:10 - 10:30

Prof. Mahmoud Marashi | United Arab Emirates

Mahmoud
Prof. Mahmoud Marashi
Consultant Haematologist | United Arab Emirates

"Prof. Mahmoud Marashi joined Mediclinic City Hospital as Consultant Haematologist with over 30 years experience in haematology. He established the clinical haematology service in Dubai Health Authority which is involved in the management of both benign disorders (anaemias, bleeding disorders, thrombosis/thrombophilia) and malignant disorders (acute and chronic leukaemias, myeloma, myeloproliferative disorders, myelodysplastic syndrome). He runs both an undergraduate and postgraduate training in Haematology. Prof. Marashi did his undergraduate training in Andhra University, India. His haematology training was done in the UL at Heartlands Hospital, Birmingham, (formerly East Birmingham Hospital), The West Midlands Blood Transfusion Service, Edgbaston, Birmingham, The John Radcliffe Hospital and Chuchill Hospital in Oxford, UK. Prof. Marashi has been involved in medical education for over 20 years. He is a Professor of Medicine and Haematology and is the Head of the Academic Department of Medicine, Dubai Medical College / Dubai Health Authority. He is also an external examiner for the Royal College of Physicians of UK. *Independent Doctors (ID): Defined as individuals not employed by Mediclinic Middle East who are granted the privilege to treat patient at MCME facilities, in either inpatient or outpatient settings, as applicable."

Lectures by this speaker
Saturday, 2022-11-26
Treating CLL in 2022: A Critical Evaluation of BTKis and Other Novel Agents

  08:30 - 08:50

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Saturday, 2022-11-26
A new Era in Front-Line CLL Management - Supported by Janssen

  09:50 - 10:10

Dr. Faraz Khan | United Arab Emirates

Faraz
Dr. Faraz Khan
Head Of Hematology Program | United Arab Emirates

Asst Prof Dr. Faraz Khan is a Consultant Hematologist and Medical Oncologist with over 15 years experience in treating cancer and various blood diseases. He completed his Internal Medicine, Hematology and Medical oncology training from the University of Connecticut, CT, USA and is triple board certified in Internal medicine, Hematology and Medical Oncology. He worked as a consultant Hematologist/Medical Oncologist at PEI Cancer Treatment Center, PE, Canada and directed the provincial hemophilia and bleeding disorder clinic.

Sessions by this speaker
Saturday, 2022-11-26
Session 2: Haematological Malignancies

  08:30 - 11:00

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Saturday, 2022-11-26
Single agent checkpoint inhibitor + chemotherapy is the preferred option?

  16:20 - 16:40

Saturday, 2022-11-26
Voting + Panel discussion

  17:00 - 17:10

Dr. Shahrukh Hashmi | United Arab Emirates

Shahrukh
Dr. Shahrukh Hashmi
Chairman | United Arab Emirates

"Dr. Shahrukh Hashmi is the acting Dean of Research at SSMC, Abu Dhabi, UAE. He graduated from Baqai Medical University, Pakistan, as the top graduate receiving Gold Medal from the President of Pakistan. He received Master’s Degree (MPH) from Yale University, Connecticut, USA. He is a Diplomat of the American Board of Preventive Medicine/Public Health, Internal Medicine, and Hematology. He has been at Mayo Clinic, Minnesota, USA for >10 years. He started Mayo Clinic’s first BMT survivorship program. He has served as PI or Co-PI on many industry-sponsored and NIH sponsored trials. His research interests include premature aging, artificial intelligence, and GVHD. He is also involved in Stem Cell Therapeutics particularly in regenerative hematology. He has authored >220 articles in peer-reviewed journals, including in JAMA, Lancet, and in NEJM. He chairs many national or international professional committees/groups including being the chair of the Worldwide Network for Blood and Marrow Transplant’s Nuclear Accident committee (Geneva, Switzerland), founding chair of American Society for Blood and Marrow Transplant Society’s Survivorship SIG (Chicago, Illinois), and co-chair of the Center for International Blood & Marrow Transplant Registry’s (CIBMTR) Health Services Committee (Milwaukee, Wisconsin). He is currently the chairperson of the Dept. of Hematology/Oncology at the SSMC, Abu Dhabi, UAE, and the chairperson of SEHA Oncology Council. He is also faculty at Khalifa University, UAE, and adjunct faculty at Mohamad Bin Zayed University of Artificial Intelligence, UAE."

Sessions by this speaker
Saturday, 2022-11-26
Session 2: Haematological Malignancies

  08:30 - 11:00

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Dr. Syed Mansoor Hasnain | United Arab Emirates

Syed Mansoor
Dr. Syed Mansoor Hasnain
Consultant Radiation Oncologist | United Arab Emirates

"Dr. Syed Mansoor Hasnain is working in Tawam Hospital, Alain, UAE as Consultant Radiation Oncologist. He joined Tawam Hospital in 2009. He initially trained as surgeon and did fellowship in surgery ,FRCS(Glasg) from Royal College Of Physicians and Surgeons Of Glasgow in 2000. In 2001 he started his career and specialist registrar Training in radiation Oncology under supervision of Faculty of Radiology, The Royal College Of Surgeons In Ireland in Saint Luke’s Hospital. He passed FRCR part 1 from Royal College of Radiologists, London U.K. He did fellowship in radiotherapy ‘FFR RCSI’ from Faculty of Radiology , Royal College Of Surgeons In Ireland in 2007. In 2010 he got CCST 'completion of certified specialist training certificate’ from Faculty of Radiology, The Royal College Of Surgeons In Ireland and entry in to specialist register in Medical Council of Ireland. In Tawam in early 2011, Dr. Mansoor successfully led the commissioning and clinical use of the HiArt TomoTherapy system with IMRT & IGRT, one and only in UAE. . In 2013 Dr. Mansoor chaired RapidArc committee, making sure smooth and swift implementation of RapidArc technology with IMRT & IGRT capability in Tawam. In 2015 Dr. Mansoor was appointed as Adjunct Assistant Professor in College of Medicine and health Sciences in UAE University. . In 2018 as lead radiation oncologist, he successfully led the QUATRO certification of the radiotherapy department by IAEA. He is clinical lead Radiation oncologist for Lymphoma, Sarcoma, Urology & GI tumours. "

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Saturday, 2022-11-26
CNS Lymphoma debate There is a role of radiotherapy in primary CNS Lymphoma

  08:50 - 09:10

Sunday, 2022-11-27
Hepatocellular Carcinoma and Cholangiocarcinoma- Case Based Discussions

  16:00 - 16:40

Sunday, 2022-11-27
Case Presentation Breast Cancer

  14:45 - 15:30

Prof. Giovanni Martinelli | Italy

Giovanni
Prof. Giovanni Martinelli
Associate Professor | Italy

Prof. Giovanni Martinelli Scientific Director Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl – IRCCS - Italy. His research and clinical activity involve the area of acute and chronic myeloid leukemia (AML and CML), acute lymphoblastic leukemia (ALL) and myelodisplastic syndromes (MDS). His expertise is in Conduction of several Phase I-II-III clinical trials and biological research projects on AML, ALL, MDS and CML as Principal Investigator, with good knowledge of Good Clinical Practice. He has the skills, expertise and authority to lead a team and he has the capacity of using the resources in a flexible way, to achieve the project objectives.

Lectures by this speaker
Saturday, 2022-11-26
Is there a role for intensive chemotherapy for AML in 2022?

  09:30 - 09:50

Saturday, 2022-11-26
Be Ready for R/R AML – approach for FLT3+ Patients - Supported by Astellas

  10:10 - 10:30

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Dr. Amar Lal | United Arab Emirates

Amar
Dr. Amar Lal
Hematologist and Oncologist | United Arab Emirates

"Dr. Amar Lal graduated from Dow University in 1993. He underwent medicine residency and followed by oncology fellowship. He qualified triple diploma in medicine, family medicine and oncology from CPSP Pakistan. Then he got triple diplomas from Royal Colleges of Physicians Ireland and Glasgow in medicine and speciality certificates oncology royal college London. He also qualified ESMO Examination Board in oncology. He has been local and international speaker in hematology and oncology and has more than 40 publications. He joined Tawam hospital in 2007 and he continued to be an active part of CME/ Scientific Program Coordinator, Member of Pharmacy & Therapeutics Committee (PTC), Patient safety physician manager, Member of Medication Utilization Committee (MSSC). "

Sessions by this speaker
Saturday, 2022-11-26
Session 2: Haematological Malignancies

  08:30 - 11:00

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Dr. Arif Raza Alam | United Arab Emirates

Arif
Dr. Arif Raza Alam
Chief of Hematology | United Arab Emirates

Chief of Hematology – Tawam Hospital

Sessions by this speaker
Friday, 2022-11-25
Scientific Committee

  00:00 - 23:55

Lectures by this speaker
Saturday, 2022-11-26
Welcome Note

  08:30 - 08:32

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  10:30 - 10:40

Saturday, 2022-11-26
A new Era in Front-Line CLL Management - Supported by Janssen

  09:50 - 10:10

  10:30 - 10:40

COFFEE BREAK

  10:40 - 11:00

Session 4: Palliative Care
Chairperson:

Dr. Mona Tareen | United Arab Emirates

Mona
Dr. Mona Tareen
Consultant in Palliative, Geriatric and Internal Medicine | United Arab Emirates

Dr. Mona Tareen is a Consultant in Palliative, Geriatric and Internal Medicine. She obtained her basic medical degree from Dhow Medical College, Karachi, Pakistan and completed her US Board Certification in Internal Medicine, Geriatrics Board Certification and Hospice and Palliative Medicine. She has worked as Palliative Medicine Consultant and Medical Director of Hospice and Palliative Care Program in the US and also served the Rush University Medical Center, Chicago, as Consultant Geriatrician.

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -


Chairperson:

Dr. Muhammad Zafar Javed | United Arab Emirates

Muhammad Zafar
Dr. Muhammad Zafar Javed
Chief of Palliative Care Clinics | United Arab Emirates

Chief of Palliative Care Clinics – Tawam Hospital

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -


  11:00 - 14:00

Introduction

Dr. Muhammad Zafar Javed | United Arab Emirates

Muhammad Zafar
Dr. Muhammad Zafar Javed
Chief of Palliative Care Clinics | United Arab Emirates

Chief of Palliative Care Clinics – Tawam Hospital

Sessions by this speaker
Friday, 2022-11-25
Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 4: Palliative Care

  11:00 - 14:00

Lectures by this speaker
Saturday, 2022-11-26
Introduction

  11:00 - 11:05

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  12:40 - 13:00

  11:00 - 11:05

Palliative Care in/is the Future of Oncology

Dr. Justin Sanders | Canada

Justin
Dr. Justin Sanders
Associate Professor of Family Medicine | Canada

Dr. Justin Sanders is the Kappy and Eric M. Flanders Chair of Palliative Care, Director of Palliative Care, and Associate Professor of Family Medicine at McGill University. Dr. Sanders qualitative and mixed-methods research focuses on cross-cultural serious illness communication and authentic healing relationships in order to drive quality and equity in the care of those affected by advanced cancer and other serious illnesses. Dr. Sanders completed fellowship training in Palliative Care at Massachusetts General Hospital and the Dana-Farber Cancer Institute in 2014, where he remained on the faculty at Harvard Medical School until 2021. As an associate faculty member at Ariadne Labs, a health systems innovation center at the Brigham and Women's Hospital and the Harvard T.H. Chan School of Public Health, Dr. Sanders continues to work on system level approaches to improving serious illness communication and care.

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  12:40 - 13:00

Saturday, 2022-11-26
Palliative Care in/is the Future of Oncology

  11:05 - 11:50

  11:05 - 11:50

Cancer Pain Management – from basics to complex

Dr. Amna AlHarrasi | Oman

Amna
Dr. Amna AlHarrasi
Palliative Care and Cancer pain Consultant | Oman

Dr Amna Ahmed Al Harrasi, a Palliative Care and Cancer pain Consultant at Sultan Qaboos Comprehensive Cancer care and research center since September 2021. Dr Amna’s Educational background started with MD degree obtained from Sultan Qaboos University in 2010 followed by Postgraduate Residency in Family medicine from Oman Medical Specialty Board in 2015. Dr Amna developed special interest in the field of palliative care and pursued further qualification in Palliative care residency from McGill University from 2018-2019 followed by advanced study of Cancer pain fellowship from McGill University as well in 2019-2020. She worked in the field of primary care as family physician from 2015-2018. Dr Amna’s current clinical work is focused on palliative care and cancer pain management at Sultan Qaboos Comprehensive care and research center (2021-2022). Her initial research interest was general medicine and primary care. Her current interests are palliative care especially in gastrointestinal malignancies and cancer pain research. Dr Amna is a member of many international medical Societies including MASCC, EFIC, NCCN, ESMO and ASCO.

Lectures by this speaker
Saturday, 2022-11-26
Cancer Pain Management – from basics to complex

  11:50 - 12:15

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  12:40 - 13:00

  11:50 - 12:15

Forgotten symptoms- in palliative care

Dr. Katie Sweeting | United Arab Emirates

Katie
Dr. Katie Sweeting
Specialist Palliative Care | United Arab Emirates

Dr. Katie completed specialist training in London and South East England to become a consultant in palliative medicine in 2009, working in both acute hospital and hospice settings. She has extensive experience of managing symptoms, concerns and expectations of patients with advanced cancer and other life-limiting illnesses. She is accredited by the Royal College of Physicians (UK) as both an educational supervisor and mentor.

Lectures by this speaker
Saturday, 2022-11-26
Forgotten symptoms- in palliative care

  12:15 - 12:40

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  12:40 - 13:00

  12:15 - 12:40

Panel Discussion and Q&A’s

Dr. Mona Tareen | United Arab Emirates

Mona
Dr. Mona Tareen
Consultant in Palliative, Geriatric and Internal Medicine | United Arab Emirates

Dr. Mona Tareen is a Consultant in Palliative, Geriatric and Internal Medicine. She obtained her basic medical degree from Dhow Medical College, Karachi, Pakistan and completed her US Board Certification in Internal Medicine, Geriatrics Board Certification and Hospice and Palliative Medicine. She has worked as Palliative Medicine Consultant and Medical Director of Hospice and Palliative Care Program in the US and also served the Rush University Medical Center, Chicago, as Consultant Geriatrician.

Sessions by this speaker
Saturday, 2022-11-26
Session 4: Palliative Care

  11:00 - 14:00

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  12:40 - 13:00

Dr. Justin Sanders | Canada

Justin
Dr. Justin Sanders
Associate Professor of Family Medicine | Canada

Dr. Justin Sanders is the Kappy and Eric M. Flanders Chair of Palliative Care, Director of Palliative Care, and Associate Professor of Family Medicine at McGill University. Dr. Sanders qualitative and mixed-methods research focuses on cross-cultural serious illness communication and authentic healing relationships in order to drive quality and equity in the care of those affected by advanced cancer and other serious illnesses. Dr. Sanders completed fellowship training in Palliative Care at Massachusetts General Hospital and the Dana-Farber Cancer Institute in 2014, where he remained on the faculty at Harvard Medical School until 2021. As an associate faculty member at Ariadne Labs, a health systems innovation center at the Brigham and Women's Hospital and the Harvard T.H. Chan School of Public Health, Dr. Sanders continues to work on system level approaches to improving serious illness communication and care.

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  12:40 - 13:00

Saturday, 2022-11-26
Palliative Care in/is the Future of Oncology

  11:05 - 11:50

Dr. Amna AlHarrasi | Oman

Amna
Dr. Amna AlHarrasi
Palliative Care and Cancer pain Consultant | Oman

Dr Amna Ahmed Al Harrasi, a Palliative Care and Cancer pain Consultant at Sultan Qaboos Comprehensive Cancer care and research center since September 2021. Dr Amna’s Educational background started with MD degree obtained from Sultan Qaboos University in 2010 followed by Postgraduate Residency in Family medicine from Oman Medical Specialty Board in 2015. Dr Amna developed special interest in the field of palliative care and pursued further qualification in Palliative care residency from McGill University from 2018-2019 followed by advanced study of Cancer pain fellowship from McGill University as well in 2019-2020. She worked in the field of primary care as family physician from 2015-2018. Dr Amna’s current clinical work is focused on palliative care and cancer pain management at Sultan Qaboos Comprehensive care and research center (2021-2022). Her initial research interest was general medicine and primary care. Her current interests are palliative care especially in gastrointestinal malignancies and cancer pain research. Dr Amna is a member of many international medical Societies including MASCC, EFIC, NCCN, ESMO and ASCO.

Lectures by this speaker
Saturday, 2022-11-26
Cancer Pain Management – from basics to complex

  11:50 - 12:15

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  12:40 - 13:00

Dr. Katie Sweeting | United Arab Emirates

Katie
Dr. Katie Sweeting
Specialist Palliative Care | United Arab Emirates

Dr. Katie completed specialist training in London and South East England to become a consultant in palliative medicine in 2009, working in both acute hospital and hospice settings. She has extensive experience of managing symptoms, concerns and expectations of patients with advanced cancer and other life-limiting illnesses. She is accredited by the Royal College of Physicians (UK) as both an educational supervisor and mentor.

Lectures by this speaker
Saturday, 2022-11-26
Forgotten symptoms- in palliative care

  12:15 - 12:40

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  12:40 - 13:00

Dr. Nandan Shanbagh | United Arab Emirates

Nandan
Dr. Nandan Shanbagh
Specialist in Radiation Oncology and Palliative Care | United Arab Emirates

Dr Nandan Shanbhag is a specialist in Radiation Oncology and Palliative Care. After completing his Bachelor’s in Medicine and Surgery (MBBS) and Post Graduate degree in Radiation Oncology from India, he completed his diploma in Palliative Medicine at the University of Cape Town in South Africa. He has worked in several countries across the world and helped establish cancer departments in India, Botswana, Bahrain and Antigua and Barbuda. He holds special research interest in application of Machine Learning in Oncology and Palliative care. He also completed his Executive Masters in Business Administration and remains an active member at various societies related to Oncology.

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion and Q&A’s

  12:40 - 13:00

Dr. Muhammad Zafar Javed | United Arab Emirates

Muhammad Zafar
Dr. Muhammad Zafar Javed
Chief of Palliative Care Clinics | United Arab Emirates

Chief of Palliative Care Clinics – Tawam Hospital

Sessions by this speaker
Friday, 2022-11-25
Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 4: Palliative Care

  11:00 - 14:00

Lectures by this speaker
Saturday, 2022-11-26
Introduction

  11:00 - 11:05

Saturday, 2022-11-26
Panel Discussion and Q&A’s

  12:40 - 13:00

  12:40 - 13:00

LUNCH BREAK

  13:00 - 14:00

Session 6: Radiation oncology session
Chairperson:

Dr. Abdulrahman Sulaiman Bin Sumaida | United Arab Emirates

Abdulrahman
Dr. Abdulrahman Sulaiman Bin Sumaida
Chief of Radiotherapy | United Arab Emirates

Chief of Radiotherapy - Tawam Hospital

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -


Chairperson:

Dr. Rana Mahmood | United Arab Emirates

Rana
Dr. Rana Mahmood
Consultant Oncologist | United Arab Emirates

Dr Rana Mahmood trained in UK and has been a consultant in oncology for last 15 years. Dr Mahmood has special interest in advance image guided radiotherapy, SABR and image based High Dose rate Brachytherapy. He is the first to introduce and only practitioner to provide Gynaecological interstitial brachytherapy in UAE. He has setup the only service in UAE to provide prostate Brachytherapy and trans-perineal spacer device. He has been principal investigator for several landmark radiotherapy trials and extensively published his work.

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -


Chairperson:

Dr. Fady Geara | United Arab Emirates

Fady
Dr. Fady Geara
Department Chair of Radiation Oncology | United Arab Emirates

"Dr. Fady Geara MD, PhD, is Department Chair of Radiation Oncology at Cleveland Clinic Abu Dhabi. Prior to joining Cleveland Clinic Abu Dhabi, Dr. Geara served as Professor and Chairman of Radiation Oncology at the American University of Beirut Medical Center, Lebanon, after having been recruited from the University of Texas MD Anderson Cancer Center in Houston, Texas, US. Dr. Geara received his medical degree from the University of Paris XI, France, and completed his residency and fellowship at the University of Texas MD Anderson Cancer Center in Houston, Texas, US. Throughout his tenure, Dr. Geara has developed many state-of-the-art radiation oncology procedures. He developed the first high dose rate brachytherapy program in the Middle East, as well as the first Stereotactic Radiosurgery program. Over the years, Dr. Geara has become established as both a regional and international leader within his specialty. "

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -


Chairperson:

Dr. Suliman Al Ghamdi | Saudi Arabia

Suliman
Dr. Suliman Al Ghamdi
Head | Saudi Arabia

"Dr. Suliman Al Ghamdi joined King Abdulaziz Medical City, Western Region in August 2005 as Associate Consultant, Department of Oncology, and promoted to Consultant position in 2007 and was appointed as Section Head, Radiation Oncology in August 2007. In August 2010, he was appointed as Deputy Chairman, Princess Noorah Oncology Center, King Abdulaziz Medical City, Western Region. In August 2011 till August 2020, he was appointed as Head, King Abdullah International Medical Research Center, Western Region. Dr. Suliman Al Ghamdi graduated from King Abdulaziz University, Faculty of Medicine, Jeddah, Saudi Arabia in 1997, and completed his internship in the same institution in 1998. He completed his Residency Training Program in Radiation Oncology from January 2000 till December 2004 at Ottawa Regional Cancer Centre, University of Ottawa, Ontario, Canada, followed by fellowship training in Radiation Oncology with sub - specialization in Stereotactic Radiosurgery of Head and Neck, CNS Malignancies and Brachytherapy in 2005. He also obtained FRCPC certificate on May 28, 2004. "

Sessions by this speaker
Thursday,

  -


  14:00 - 15:40

SBRT for Spine: Necessity or Luxury?

Dr. Majed Al Ghamdi | Saudi Arabia

Majed
Dr. Majed Al Ghamdi
Assistant Professor and Consultant Radiation Oncologist | Saudi Arabia

Dr. Alghamdi, MD, MBA, FRCPC, DABR is an assistant professor and consultant radiation oncologist with a sub-specialization in treating central nervous system (CNS) tumors and stereotactic radiosurgery. He completed his residency training at university of Calgary, Alberta, Canada in 2016 and his fellowship training at university of Toronto, Ontario, Canada in 2017. He holds Canadian and American boards in radiation oncology. He has published three textbook chapters and numerous peer-reviewed manuscripts that mainly focused on CNS oncology. Recently, Dr. Alghamdi completed masters degree in business administration from prince Mohammad Bin Salman College of Business and Entrepreneurship.

Lectures by this speaker
Saturday, 2022-11-26
SBRT for Spine: Necessity or Luxury?

  14:00 - 14:20

Saturday, 2022-11-26
Panel Discussion

  15:20 - 15:30

Saturday, 2022-11-26
Stereotactic Radiosurgery for Brain Metastases: An Update

  16:20 - 16:40

Saturday, 2022-11-26
Panel Discussion

  17:20 - 17:30

  14:00 - 14:20

Lung SABR: A Practical Guide for the Radiation Oncologist

Dr. Paul Kelly | Ireland

Paul
Dr. Paul Kelly
Consultant Radiation Oncologist | Ireland

Dr Paul Kelly is a graduate of University College Cork and completed General Professional Training in medicine at the Mater Hospital, Dublin. Having acquired Membership of the Royal College of Physicians he completed specialist training in Radiation Oncology at St Luke’s Hospital in Dublin. He became a Fellow of the Faculty of Radiology at the Royal College of Surgeons in Ireland in 2008 and, thereafter, completed a 2-year Clinical Fellowship in Stereotactic Radiosurgery at Brigham and Women’s Hospital/Dana-Farber Cancer Institute in Boston, Massachusetts. Based in Cork since 2011 as a Consultant Radiation Oncologist he is active in clinical research and co-chairs the GU disease-specific subgroup (DSSG) of Cancer Trials Ireland. His chief interests include prostate cancer, brain tumours, stereotactic radiotherapy and prostate seed brachytherapy. He took up a position as Medical Director of the new radiation oncology facility at the Bon Secours Radiotherapy Centre joint venture with University of Pittsburgh Medical Centre (UPMC) Hillman Cancer Centre in 2019.

Lectures by this speaker
Saturday, 2022-11-26
Lung SABR: A Practical Guide for the Radiation Oncologist

  14:20 - 14:40

Saturday, 2022-11-26
Panel Discussion

  15:20 - 15:30

Sunday, 2022-11-27
Evolving role of SBRT in Localised Prostate cancer

  08:50 - 09:10

Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting

  09:50 - 10:00

  14:20 - 14:40

Advances in Prostate Radiotherapy

Dr. Nadeem Pervez | Oman

Nadeem
Dr. Nadeem Pervez
Radiation Oncologist | Oman

"Dr. Nadeem Pervez qualified in Radiation Oncologist from Ireland and Canada. He worked in Ireland, Canada and Middle East at various academic levels. He served as radiation oncologist at Cross Cancer Institute and Associate Professor at University of Alberta, Edmonton, Alberta, Canada. His clinical work includes treating cancer of various sites with emphasis on breast and prostate cancer. He was a prominent member of Prostate Cancer Brachytherapy seed implantation treatment in Canada. He is initiating Prostate Brachytherapy treatment in the Middle East. He co-chaired breast cancer group in Alberta and contributed to Alberta Breast Cancer Treatment guidelines. He was involved in invention of newer radiotherapy machines. Nadeem was actively involved in contributing to Resident Training program and Clinical Research Fellowship program in Radiation Oncology at the University of Alberta, Canada. He was awarded best teacher award from residents to acknowledge his contributions. He oversees research projects from international fellows. His residents and fellows later appointed at key academic, clinical and leadership positions across world. He was invited as scientific speaker in multiple countries. Nadeem is actively involved in clinical research. He was able to secure multiple competitive research grants from awarding agencies. He was leading investigator initiated studies and involved in multi-institutional cooperative group studies. He published multiple research articles in reputed journals. He served in institutional ethics committees, research funds granting agencies, medical student selection committees, oncology conference scientific committee and peer-reviewed several Oncology journals. He is founding member in establishing Middle East Society of Therapeutic Radiation Oncology (MESTRO). "

Lectures by this speaker
Saturday, 2022-11-26
Advances in Prostate Radiotherapy

  14:40 - 15:00

Saturday, 2022-11-26
Panel Discussion

  15:20 - 15:30

Sunday, 2022-11-27
Bladder Cancer Case Based Discussion

  15:40 - 16:25

  14:40 - 15:00

Advances in Cervical Cancer Radiotherapy

Dr. Rana Mahmood | United Arab Emirates

Rana
Dr. Rana Mahmood
Consultant Oncologist | United Arab Emirates

Dr Rana Mahmood trained in UK and has been a consultant in oncology for last 15 years. Dr Mahmood has special interest in advance image guided radiotherapy, SABR and image based High Dose rate Brachytherapy. He is the first to introduce and only practitioner to provide Gynaecological interstitial brachytherapy in UAE. He has setup the only service in UAE to provide prostate Brachytherapy and trans-perineal spacer device. He has been principal investigator for several landmark radiotherapy trials and extensively published his work.

Sessions by this speaker
Saturday, 2022-11-26
Session 6: Radiation oncology session

  14:00 - 15:40

Lectures by this speaker
Saturday, 2022-11-26
Advances in Cervical Cancer Radiotherapy

  15:00 - 15:20

Saturday, 2022-11-26
Panel Discussion

  15:20 - 15:30

  15:00 - 15:20

Panel Discussion

Dr. Rana Mahmood | United Arab Emirates

Rana
Dr. Rana Mahmood
Consultant Oncologist | United Arab Emirates

Dr Rana Mahmood trained in UK and has been a consultant in oncology for last 15 years. Dr Mahmood has special interest in advance image guided radiotherapy, SABR and image based High Dose rate Brachytherapy. He is the first to introduce and only practitioner to provide Gynaecological interstitial brachytherapy in UAE. He has setup the only service in UAE to provide prostate Brachytherapy and trans-perineal spacer device. He has been principal investigator for several landmark radiotherapy trials and extensively published his work.

Sessions by this speaker
Saturday, 2022-11-26
Session 6: Radiation oncology session

  14:00 - 15:40

Lectures by this speaker
Saturday, 2022-11-26
Advances in Cervical Cancer Radiotherapy

  15:00 - 15:20

Saturday, 2022-11-26
Panel Discussion

  15:20 - 15:30

Dr. Fady Geara | United Arab Emirates

Fady
Dr. Fady Geara
Department Chair of Radiation Oncology | United Arab Emirates

"Dr. Fady Geara MD, PhD, is Department Chair of Radiation Oncology at Cleveland Clinic Abu Dhabi. Prior to joining Cleveland Clinic Abu Dhabi, Dr. Geara served as Professor and Chairman of Radiation Oncology at the American University of Beirut Medical Center, Lebanon, after having been recruited from the University of Texas MD Anderson Cancer Center in Houston, Texas, US. Dr. Geara received his medical degree from the University of Paris XI, France, and completed his residency and fellowship at the University of Texas MD Anderson Cancer Center in Houston, Texas, US. Throughout his tenure, Dr. Geara has developed many state-of-the-art radiation oncology procedures. He developed the first high dose rate brachytherapy program in the Middle East, as well as the first Stereotactic Radiosurgery program. Over the years, Dr. Geara has become established as both a regional and international leader within his specialty. "

Sessions by this speaker
Saturday, 2022-11-26
Session 6: Radiation oncology session

  14:00 - 15:40

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion

  15:20 - 15:30

Dr. Majed Al Ghamdi | Saudi Arabia

Majed
Dr. Majed Al Ghamdi
Assistant Professor and Consultant Radiation Oncologist | Saudi Arabia

Dr. Alghamdi, MD, MBA, FRCPC, DABR is an assistant professor and consultant radiation oncologist with a sub-specialization in treating central nervous system (CNS) tumors and stereotactic radiosurgery. He completed his residency training at university of Calgary, Alberta, Canada in 2016 and his fellowship training at university of Toronto, Ontario, Canada in 2017. He holds Canadian and American boards in radiation oncology. He has published three textbook chapters and numerous peer-reviewed manuscripts that mainly focused on CNS oncology. Recently, Dr. Alghamdi completed masters degree in business administration from prince Mohammad Bin Salman College of Business and Entrepreneurship.

Lectures by this speaker
Saturday, 2022-11-26
SBRT for Spine: Necessity or Luxury?

  14:00 - 14:20

Saturday, 2022-11-26
Panel Discussion

  15:20 - 15:30

Saturday, 2022-11-26
Stereotactic Radiosurgery for Brain Metastases: An Update

  16:20 - 16:40

Saturday, 2022-11-26
Panel Discussion

  17:20 - 17:30

Dr. Nadeem Pervez | Oman

Nadeem
Dr. Nadeem Pervez
Radiation Oncologist | Oman

"Dr. Nadeem Pervez qualified in Radiation Oncologist from Ireland and Canada. He worked in Ireland, Canada and Middle East at various academic levels. He served as radiation oncologist at Cross Cancer Institute and Associate Professor at University of Alberta, Edmonton, Alberta, Canada. His clinical work includes treating cancer of various sites with emphasis on breast and prostate cancer. He was a prominent member of Prostate Cancer Brachytherapy seed implantation treatment in Canada. He is initiating Prostate Brachytherapy treatment in the Middle East. He co-chaired breast cancer group in Alberta and contributed to Alberta Breast Cancer Treatment guidelines. He was involved in invention of newer radiotherapy machines. Nadeem was actively involved in contributing to Resident Training program and Clinical Research Fellowship program in Radiation Oncology at the University of Alberta, Canada. He was awarded best teacher award from residents to acknowledge his contributions. He oversees research projects from international fellows. His residents and fellows later appointed at key academic, clinical and leadership positions across world. He was invited as scientific speaker in multiple countries. Nadeem is actively involved in clinical research. He was able to secure multiple competitive research grants from awarding agencies. He was leading investigator initiated studies and involved in multi-institutional cooperative group studies. He published multiple research articles in reputed journals. He served in institutional ethics committees, research funds granting agencies, medical student selection committees, oncology conference scientific committee and peer-reviewed several Oncology journals. He is founding member in establishing Middle East Society of Therapeutic Radiation Oncology (MESTRO). "

Lectures by this speaker
Saturday, 2022-11-26
Advances in Prostate Radiotherapy

  14:40 - 15:00

Saturday, 2022-11-26
Panel Discussion

  15:20 - 15:30

Sunday, 2022-11-27
Bladder Cancer Case Based Discussion

  15:40 - 16:25

Dr. Paul Kelly | Ireland

Paul
Dr. Paul Kelly
Consultant Radiation Oncologist | Ireland

Dr Paul Kelly is a graduate of University College Cork and completed General Professional Training in medicine at the Mater Hospital, Dublin. Having acquired Membership of the Royal College of Physicians he completed specialist training in Radiation Oncology at St Luke’s Hospital in Dublin. He became a Fellow of the Faculty of Radiology at the Royal College of Surgeons in Ireland in 2008 and, thereafter, completed a 2-year Clinical Fellowship in Stereotactic Radiosurgery at Brigham and Women’s Hospital/Dana-Farber Cancer Institute in Boston, Massachusetts. Based in Cork since 2011 as a Consultant Radiation Oncologist he is active in clinical research and co-chairs the GU disease-specific subgroup (DSSG) of Cancer Trials Ireland. His chief interests include prostate cancer, brain tumours, stereotactic radiotherapy and prostate seed brachytherapy. He took up a position as Medical Director of the new radiation oncology facility at the Bon Secours Radiotherapy Centre joint venture with University of Pittsburgh Medical Centre (UPMC) Hillman Cancer Centre in 2019.

Lectures by this speaker
Saturday, 2022-11-26
Lung SABR: A Practical Guide for the Radiation Oncologist

  14:20 - 14:40

Saturday, 2022-11-26
Panel Discussion

  15:20 - 15:30

Sunday, 2022-11-27
Evolving role of SBRT in Localised Prostate cancer

  08:50 - 09:10

Sunday, 2022-11-27
Panel Discussion and Q&A’s + Voting

  09:50 - 10:00

Dr. Abdulrahman Sulaiman Bin Sumaida | United Arab Emirates

Abdulrahman
Dr. Abdulrahman Sulaiman Bin Sumaida
Chief of Radiotherapy | United Arab Emirates

Chief of Radiotherapy - Tawam Hospital

Sessions by this speaker
Friday, 2022-11-25
Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 6: Radiation oncology session

  14:00 - 15:40

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion

  15:20 - 15:30

  15:20 - 15:30

COFFEE BREAK

  15:30 - 15:40

Session 8: Neuro-Oncology
Chairperson:

Dr. Mohammad Asha | United Arab Emirates

Mohammad
Dr. Mohammad Asha
Consultant Physician, Neurosurgery Clinics | United Arab Emirates

Consultant Physician, Neurosurgery Clinics Tawam Hospital

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -

Thursday,

  -


Chairperson:

Dr. Aly Abdel Razek | United Arab Emirates

Aly Abdel
Dr. Aly Abdel Razek
Chairman and Executive Director | United Arab Emirates

Dr. Abdel Razek graduated from Cairo University. He completed his residency in 1976 at Washington University in St. Louis, Mo., USA. He is board certified in both Radiation Oncology and Pediatrics. He co-authored four text books in radiation oncology and contributed to many publications in oncology journals. He served on the national committee of the Southwest Oncology Group, Intergroup Ewings Sarcoma and National Wilms Tumor Committee. Dr. Abdel Razek is a Fellow of the American College of Radiation Oncology. He is president of Medical Resources International and Chairman and Executive Director of the Gulf International Cancer Center.

Sessions by this speaker
Thursday,

  -

Lectures by this speaker
Thursday,

  -


Chairperson:

Dr. Selvaraj Giridharan | United Arab Emirates

Selvaraj
Dr. Selvaraj Giridharan
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr Selvaraj Giridharan is a highly skilled and experienced oncologist with dual accreditation from the UK. He completed his Bachelor’s Medical degree from the University of Madras in 1993 and went on to continue his training in the UK, he became a member of Royal college of Physicians in 1998 and then achieved clinical oncology Fellowship in 2004. He worked as a consultant clinical oncologist in University Hospitals of North Midlands from 2004 to 2022 until his appointment to Tawam Hospitals in September this year. During his time in Stoke he held several additional roles including being services lead, audit lead, research lead, appraiser and clinical tutor. He has published extensively and has been a PI and SI for more than 30 clinical trials.

Sessions by this speaker
Thursday,

  -

Thursday,

  -

Lectures by this speaker
Thursday,

  -


  15:40 - 17:30

Surgical Management of Glioma - Advances and Change in Paradigm

Dr. Mohammad Asha | United Arab Emirates

Mohammad
Dr. Mohammad Asha
Consultant Physician, Neurosurgery Clinics | United Arab Emirates

Consultant Physician, Neurosurgery Clinics Tawam Hospital

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 8: Neuro-Oncology

  15:40 - 17:30

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion

  17:20 - 17:30

Saturday, 2022-11-26
Surgical Management of Glioma - Advances and Change in Paradigm

  15:40 - 16:00

  15:40 - 16:00

High-grade gliomas-State of the Art treatment in 202

Dr. Paul Sanghera | United Kingdom

Paul
Dr. Paul Sanghera
Clinical oncology consultant and honorary lecturer | United Kingdom

Following clinical oncology training in London and Birmingham, Paul undertook a brain tumour fellowship with The University of Toronto. Paul returned to The UK in 2008 and was appointed a clinical oncologist at University Hospitals Birmingham. Paul has had a busy clinical Neuro-Oncology practice since this appointment. He led the radiotherapy department between 2013 and 2018, and then the neuro-oncology tumour board from 2018. Paul is the current regional brain tumour research lead and expert advisory group chair. Paul has been an investigator on several brain tumour studies, served on trial management groups, published widely and supported national research groups working to develop new clinical trials

Lectures by this speaker
Saturday, 2022-11-26
High-grade gliomas-State of the Art treatment in 202

  16:00 - 16:20

Saturday, 2022-11-26
Panel Discussion

  17:20 - 17:30

  16:00 - 16:20

Stereotactic Radiosurgery for Brain Metastases: An Update

Dr. Majed Al Ghamdi | Saudi Arabia

Majed
Dr. Majed Al Ghamdi
Assistant Professor and Consultant Radiation Oncologist | Saudi Arabia

Dr. Alghamdi, MD, MBA, FRCPC, DABR is an assistant professor and consultant radiation oncologist with a sub-specialization in treating central nervous system (CNS) tumors and stereotactic radiosurgery. He completed his residency training at university of Calgary, Alberta, Canada in 2016 and his fellowship training at university of Toronto, Ontario, Canada in 2017. He holds Canadian and American boards in radiation oncology. He has published three textbook chapters and numerous peer-reviewed manuscripts that mainly focused on CNS oncology. Recently, Dr. Alghamdi completed masters degree in business administration from prince Mohammad Bin Salman College of Business and Entrepreneurship.

Lectures by this speaker
Saturday, 2022-11-26
SBRT for Spine: Necessity or Luxury?

  14:00 - 14:20

Saturday, 2022-11-26
Panel Discussion

  15:20 - 15:30

Saturday, 2022-11-26
Stereotactic Radiosurgery for Brain Metastases: An Update

  16:20 - 16:40

Saturday, 2022-11-26
Panel Discussion

  17:20 - 17:30

  16:20 - 16:40

Updates in Molecular markers in Chordoma management

Dr. Gelareh Zadeh | Canada

Gelareh
Dr. Gelareh Zadeh
Professor | Canada

"Dr Gelareh Zadeh is a Professor at the Department of Surgery University of Toronto. She is a Neurosurgeon-Scientist at Toronto Western Hospital, University Health Network. She was most recently appointed as the Wilkins Family Chair in Brain Tumor Research. Her clinical practice focuses on Skull Base Neuro-oncology, with dedicated general brain tumour clinic and many multidisciplinary clinics that she has established and is actively involved with such as skull base, pituitary, brain metastases, gamma knife and neurofibromatosis clinic. She is actively involved with and is dedicated to the goal of advancing surgical clinical trials. Her research laboratory is focused on studying the molecular mechanisms of glioma angiogenesis and molecular regulators of tumour metabolism. Specifically investigating the role of bone marrow derived cells in supporting tumour vasculature in gliomas and how differentiation into macrophage and microglia population plays a role in escape mechanisms of evading anti-angiogenic therapy. A second focus of the laboratory, on tumour metabolism, explores the interplay between altered metabolism in response to anti-angiogenic therapy. She also has a translational program, dedicated to establishing the genomic landscape of menigniomas and schwannomas. Her laboratory is funded through peer-reviewed grants from a number of agencies such as CIHR, Terry Fox New Investigator grant, CCSRI, CRS, BrainChild and others. She is a scientist at Labatts Brain Tumor Research at Sick Kids Research Institute and Macfeeters-Hamilton Neuro-oncology Centre at Ontario Cancer Institute. She is active in many local, national and international committees in the field of neuro-oncology. She is the director of the UHN brain tumor bank and co-director of the University of Toronto Brain Tumor Bank. Together with Dr Vera Bril she is the co-Director of the UHN Elizabeth Raab Neurofibromatosis Program. She is the Chair of Academic Affairs for Division of Neurosurgery at University of Toronto. She has served as the scientific co-chair of Society of Neuro-oncology for two years (2014 and 2015), she is currently the Secretary/Treasurer of Society of Neuro-oncology (2016 & 17) and Chairof Neuro-oncology Committee at the World Federation of Neurological Surgeons (2013-17). She is the co-chair and founder of the consortium on meningiomas, in collaboration with Society of Neuro-oncology."

Lectures by this speaker
Saturday, 2022-11-26
Updates in Molecular markers in Chordoma management

  16:40 - 17:00

Saturday, 2022-11-26
Panel Discussion

  17:20 - 17:30

  16:40 - 17:00

Updates in the management of Low grade glioma

Dr. Syed Zubair | Saudi Arabia

Syed
Dr. Syed Zubair
Consultant Medical Oncologist | Saudi Arabia

He is a Consultant Medical Oncologist at the King Faisal Specialist Hospital and Research Centre in Jeddah and have specialist interest in the management of colorectal, prostate and CNS tumors.He completed his post graduate medical education in the UK and trained as a medical Oncologist at the Yorkshire Deanery leading to a CCT in Medical Oncology. he initially worked as a Consultant Medical Oncologist at St James University Hospital in Leeds and then spent nearly a decade at the James Cook University Hospital in the North East of UK prior to moving to Jeddah. He has been involved in recruiting many patients to various phase 2 and phase 3 clinical trials during my career and currently the chairman of the Oncology Mortality and Morbidity committee at KFSHRC in Jeddah

Lectures by this speaker
Saturday, 2022-11-26
Updates in the management of Low grade glioma

  17:00 - 17:20

Saturday, 2022-11-26
Panel Discussion

  17:20 - 17:30

  17:00 - 17:20

Panel Discussion

Dr. Aly Abdel Razek | United Arab Emirates

Aly Abdel
Dr. Aly Abdel Razek
Chairman and Executive Director | United Arab Emirates

Dr. Abdel Razek graduated from Cairo University. He completed his residency in 1976 at Washington University in St. Louis, Mo., USA. He is board certified in both Radiation Oncology and Pediatrics. He co-authored four text books in radiation oncology and contributed to many publications in oncology journals. He served on the national committee of the Southwest Oncology Group, Intergroup Ewings Sarcoma and National Wilms Tumor Committee. Dr. Abdel Razek is a Fellow of the American College of Radiation Oncology. He is president of Medical Resources International and Chairman and Executive Director of the Gulf International Cancer Center.

Sessions by this speaker
Saturday, 2022-11-26
Session 8: Neuro-Oncology

  15:40 - 17:30

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion

  17:20 - 17:30

Dr. Gelareh Zadeh | Canada

Gelareh
Dr. Gelareh Zadeh
Professor | Canada

"Dr Gelareh Zadeh is a Professor at the Department of Surgery University of Toronto. She is a Neurosurgeon-Scientist at Toronto Western Hospital, University Health Network. She was most recently appointed as the Wilkins Family Chair in Brain Tumor Research. Her clinical practice focuses on Skull Base Neuro-oncology, with dedicated general brain tumour clinic and many multidisciplinary clinics that she has established and is actively involved with such as skull base, pituitary, brain metastases, gamma knife and neurofibromatosis clinic. She is actively involved with and is dedicated to the goal of advancing surgical clinical trials. Her research laboratory is focused on studying the molecular mechanisms of glioma angiogenesis and molecular regulators of tumour metabolism. Specifically investigating the role of bone marrow derived cells in supporting tumour vasculature in gliomas and how differentiation into macrophage and microglia population plays a role in escape mechanisms of evading anti-angiogenic therapy. A second focus of the laboratory, on tumour metabolism, explores the interplay between altered metabolism in response to anti-angiogenic therapy. She also has a translational program, dedicated to establishing the genomic landscape of menigniomas and schwannomas. Her laboratory is funded through peer-reviewed grants from a number of agencies such as CIHR, Terry Fox New Investigator grant, CCSRI, CRS, BrainChild and others. She is a scientist at Labatts Brain Tumor Research at Sick Kids Research Institute and Macfeeters-Hamilton Neuro-oncology Centre at Ontario Cancer Institute. She is active in many local, national and international committees in the field of neuro-oncology. She is the director of the UHN brain tumor bank and co-director of the University of Toronto Brain Tumor Bank. Together with Dr Vera Bril she is the co-Director of the UHN Elizabeth Raab Neurofibromatosis Program. She is the Chair of Academic Affairs for Division of Neurosurgery at University of Toronto. She has served as the scientific co-chair of Society of Neuro-oncology for two years (2014 and 2015), she is currently the Secretary/Treasurer of Society of Neuro-oncology (2016 & 17) and Chairof Neuro-oncology Committee at the World Federation of Neurological Surgeons (2013-17). She is the co-chair and founder of the consortium on meningiomas, in collaboration with Society of Neuro-oncology."

Lectures by this speaker
Saturday, 2022-11-26
Updates in Molecular markers in Chordoma management

  16:40 - 17:00

Saturday, 2022-11-26
Panel Discussion

  17:20 - 17:30

Dr. Paul Sanghera | United Kingdom

Paul
Dr. Paul Sanghera
Clinical oncology consultant and honorary lecturer | United Kingdom

Following clinical oncology training in London and Birmingham, Paul undertook a brain tumour fellowship with The University of Toronto. Paul returned to The UK in 2008 and was appointed a clinical oncologist at University Hospitals Birmingham. Paul has had a busy clinical Neuro-Oncology practice since this appointment. He led the radiotherapy department between 2013 and 2018, and then the neuro-oncology tumour board from 2018. Paul is the current regional brain tumour research lead and expert advisory group chair. Paul has been an investigator on several brain tumour studies, served on trial management groups, published widely and supported national research groups working to develop new clinical trials

Lectures by this speaker
Saturday, 2022-11-26
High-grade gliomas-State of the Art treatment in 202

  16:00 - 16:20

Saturday, 2022-11-26
Panel Discussion

  17:20 - 17:30

Dr. Majed Al Ghamdi | Saudi Arabia

Majed
Dr. Majed Al Ghamdi
Assistant Professor and Consultant Radiation Oncologist | Saudi Arabia

Dr. Alghamdi, MD, MBA, FRCPC, DABR is an assistant professor and consultant radiation oncologist with a sub-specialization in treating central nervous system (CNS) tumors and stereotactic radiosurgery. He completed his residency training at university of Calgary, Alberta, Canada in 2016 and his fellowship training at university of Toronto, Ontario, Canada in 2017. He holds Canadian and American boards in radiation oncology. He has published three textbook chapters and numerous peer-reviewed manuscripts that mainly focused on CNS oncology. Recently, Dr. Alghamdi completed masters degree in business administration from prince Mohammad Bin Salman College of Business and Entrepreneurship.

Lectures by this speaker
Saturday, 2022-11-26
SBRT for Spine: Necessity or Luxury?

  14:00 - 14:20

Saturday, 2022-11-26
Panel Discussion

  15:20 - 15:30

Saturday, 2022-11-26
Stereotactic Radiosurgery for Brain Metastases: An Update

  16:20 - 16:40

Saturday, 2022-11-26
Panel Discussion

  17:20 - 17:30

Dr. Syed Zubair | Saudi Arabia

Syed
Dr. Syed Zubair
Consultant Medical Oncologist | Saudi Arabia

He is a Consultant Medical Oncologist at the King Faisal Specialist Hospital and Research Centre in Jeddah and have specialist interest in the management of colorectal, prostate and CNS tumors.He completed his post graduate medical education in the UK and trained as a medical Oncologist at the Yorkshire Deanery leading to a CCT in Medical Oncology. he initially worked as a Consultant Medical Oncologist at St James University Hospital in Leeds and then spent nearly a decade at the James Cook University Hospital in the North East of UK prior to moving to Jeddah. He has been involved in recruiting many patients to various phase 2 and phase 3 clinical trials during my career and currently the chairman of the Oncology Mortality and Morbidity committee at KFSHRC in Jeddah

Lectures by this speaker
Saturday, 2022-11-26
Updates in the management of Low grade glioma

  17:00 - 17:20

Saturday, 2022-11-26
Panel Discussion

  17:20 - 17:30

Dr. Mohammad Asha | United Arab Emirates

Mohammad
Dr. Mohammad Asha
Consultant Physician, Neurosurgery Clinics | United Arab Emirates

Consultant Physician, Neurosurgery Clinics Tawam Hospital

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 8: Neuro-Oncology

  15:40 - 17:30

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion

  17:20 - 17:30

Saturday, 2022-11-26
Surgical Management of Glioma - Advances and Change in Paradigm

  15:40 - 16:00

Dr. Selvaraj Giridharan | United Arab Emirates

Selvaraj
Dr. Selvaraj Giridharan
Consultant Physician, Oncology Clinic | United Arab Emirates

Dr Selvaraj Giridharan is a highly skilled and experienced oncologist with dual accreditation from the UK. He completed his Bachelor’s Medical degree from the University of Madras in 1993 and went on to continue his training in the UK, he became a member of Royal college of Physicians in 1998 and then achieved clinical oncology Fellowship in 2004. He worked as a consultant clinical oncologist in University Hospitals of North Midlands from 2004 to 2022 until his appointment to Tawam Hospitals in September this year. During his time in Stoke he held several additional roles including being services lead, audit lead, research lead, appraiser and clinical tutor. He has published extensively and has been a PI and SI for more than 30 clinical trials.

Sessions by this speaker
Friday, 2022-11-25
Sub Scientific Committee

  00:00 - 23:55

Saturday, 2022-11-26
Session 8: Neuro-Oncology

  15:40 - 17:30

Lectures by this speaker
Saturday, 2022-11-26
Panel Discussion

  17:20 - 17:30

  17:20 - 17:30


Congress Secretariat :
INDEX Conferences & Exhibitions Org. Est.
INDEX Conferences & Exhibitions Org. Est.

COPYRIGHT © 2023. ALL RIGHTS RESERVED.